Subject Index to Volume 74

A

ABC transporter family, P-glycoprotein (mdr1), 822
Abdominal chemoreceptors. *See* Peripheral chemoreceptors
Acetylcholine
  carotid body chemoreceptor response to, 858
  carotid body metabolism, 846
  leak, 946–947
  neurotransmission at carotid body chemoreceptor cell-sensory nerve ending synapse and, 876
  release
    carotid body chemoreceptor output and, 847–848
    quantal. *See* Quantal acetylcholine release
  synthesis, regulation of, 945
  turnover, 945–946
Acid-base balance, ectothermic vertebrate heart, 240–241
Acidosis, cardiac contractility and. *See* Ectothermic vertebrate heart
Adenosine, short-term regulation of quantal acetylcholine release, 952
Adenosine 3′,5′-cyclic monophosphate (cAMP)
  carotid body chemoreceptor cell function and, 873
  effects of calcium-magnesium-adenosinetriphosphatase, 695
  facilitation of calcium channel currents, 387–388
  sodium-potassium-chloride cotransport in vascular smooth muscle, 707
Adenosine 3′,5′-cyclic monophosphate (cAMP) second messenger system, modulation of L-type calcium channels in muscle cells
  cardiac muscle, 407–409
    channel dephosphorylation, 409
    elevation of cAMP concentration, 408
    modification of adenosine 5′-triphosphate supply/utilization, 408–409
    modification of cAMP-dependent protein kinase activity, 408
  L-type channel subunits and cAMP-dependent phosphorylation, 410–411
  on physical basis of phosphorylation-induced stimulation, 411
  skeletal muscle L-type channels, 409–410
  smooth muscle L-type channels, 410
Adenosine 5′-diphosphate, ectothermic vertebrate heart, hypoxia and, 236–237
Adenosinetriphosphatase
  calcium. *See* Calcium-adenosinetriphosphatase
  calcium-magnesium. *See* Calcium-magnesium-adenosinetriphosphatase
  potassium-hydrogen, 689–690
  sarcoplasmic reticulum, pH and, 69–70
  sodium-potassium. *See* Sodium-potassium-adenosinetriphosphatase
Adenosine 5′-triphosphate
  corelease with acetylcholine, 949
  intracellular, muscle fatigue and, 72–74
  potassium currents, 908
Adiposity. *See* Body fat distribution; Obesity
Adrenal hormones, peripheral chemoreceptor stimulation and, 571–572
Adrenergic agonists
  sodium-hydrogen exchange in vascular smooth muscle and, 699
  sodium-potassium-chloride cotransport in vascular smooth muscle, 707
α-Adrenergic receptors, stimulation, calcium channel modulation in muscle cells, 423–425
β-Adrenergic receptors, stimulation, calcium channel modulation in muscle cells, 417–421
Aequorins, chimeric aequorins as intraorganelle calcium probes, 624–625
Afferent innervation, viscera, 98–99
  sympathetic and parasympathetic afferents, 99
Afferent pathways. *See* Sympathetic afferent fibers; Vagal afferent fibers
Age/aging
  cellular defenses in aging process, 151–153
  free radical theory of aging, 151–152
  synaptic efficacy at neuromuscular junction and, 954
Airway receptors, upper, interactions with peripheral chemoreceptors, 573–574
Airways. *See* Respiratory system
Albumin
  differential steady-state albumin fluxes in small and large pores: relationships between diffusive and convective fluxes, 183–185. *See also* Transvascular transport
  vascular large-solute permeability and, 206–207
Alcohol ingestion, body fat distribution and, 779–780
Alcohols, calcium channel modulation in muscle cells, 446
Alpha-associated factor, in DNA replication, 270
Amphibians, heart metabolism and contractility. *See* Ectothermic vertebrate heart
Amygdala, control of cardiovascular sympathetic premotor neurons, 345
Amyotrophic lateral sclerosis, quantal acetylcholine release in, 955
Anesthesia, depth of, investigation by tools derived from theory of dynamic systems, 37–38
Angina pectoris, 101
Angiotensin II
  receptor-mediated modulation of calcium channels in muscle cells, 428
  sodium-hydrogen exchange in vascular smooth muscle and, 698
  sodium-potassium-chloride cotransport in vascular smooth muscle, 706
Anthropometry, 767–768
Antioxidant defense systems, 142–146
  antioxidants, 142–145. *See also* Antioxidants
  antioxidant scavenging enzymes, 145–146
    catalase, 145
    glutathione peroxidase, 145–146
    superoxide dismutase, 145
  primary defenses, 142–146
    antioxidants, 142–145
    antioxidant scavenging enzymes, 145–146
  secondary defenses, 146
    lipolytic enzymes, 146
    proteolytic enzymes, 146
  synergistic actions of vitamins E and C, 148–149
Antioxidants, 142–145
  glutathione, 144
  synergistic actions of vitamins E and C, 148–149
  uric acid, 144–145
  vitamin A, 144
  vitamin C, 143–144
  vitamin E, 142–143
Antiporter(s)
  hydrogen (sodium)-calcium, 601
  sodium-hydrogen, vascular smooth muscle, 696–702
Aortic body chemoreceptors. *See* Peripheral chemoreceptors
Arabinonucleosides, inhibition of DNA polymerases, 285–286
Arachidonic acid, NMDA receptor function and, 736–737

Area postrema, control of cardiovascular sympathetic premotor neurons, 341–342
Arterial pressure, peripheral chemoreceptor function and, 546
Artery(ies), pain sensitivity, 103
Ascorbic acid. *See* Vitamin C
Atherosclerosis, cellular defenses in, 153–154
ATPase. *See* Adenosinetriphosphatase
Atrial natriuretic peptide
receptor-mediated modulation of calcium channels in muscle cells, 429–430
sodium-hydrogen exchange in vascular smooth muscle and, 699
sodium-potassium-chloride cotransport in vascular smooth muscle, 706–707
Attractors, 11, 638–640
characterization of, fractal dimension, metric entropy, and spectrum of Lyapunov exponents, 15–22
strange, quantitative methods for detection of, 642–644
Auditory cortex, chaotic behavior, dimensional evaluations in cats, 32–33
Augmentation, quantal acetylcholine release, 920, 958
Autacoids, vascular large-solute permeability and, 205–206
Autoregulation, 667–673
dynamics of, 668–670
mathematical models of dynamic autoregulation of renal blood flow, 670–673
differences in hypertension, 672
nonlinear analysis, 672–673
renin-angiotensin system in, 672
mechanisms of, 667–668
myogenic response of vascular smooth muscle in, 659–664

B

Bacteriophage λ O protein, DNA replication, 265
Barium, intracellular, inhibition of calcium channels in muscle cells, 405
Baroreceptor reflex, central pathways mediating, 347–348
cardiac component, 348
endocrine component, 348
vasomotor component, 347–348
Baroreceptors, interactions with peripheral chemoreceptors, 574–575
Benzothiazipines, modulation of calcium channels in muscle cells, 433–441
Bezold-Jarisch reflex, 350
Bicarbonate, ectothermic vertebrate heart, 240–241
contractility and, 241–242
Biliary system
nociceptors, 111
pain, 109
sensory innervation, 110
Bladder
pain sensation, 117, 119
sensations from, 116–117
sensory innervation, 117–119
chemoreceptors, 118–119
mechanoreceptors, 117–118
Blood flow
autoregulation. *See* Autoregulation
renal. *See* Kidney, blood flow regulation
Blood glucose, muscle fatigue and, 76–77
Blood pressure
body fat distribution and, 789–790
variability in conscious animals, 647–648
Blood vessels
ion transport in vascular smooth muscle cells. *See* Vascular smooth muscle
macromolecular transport across microvascular walls, 163–219. *See also* Transvascular transport
pain sensitivity, 103–104
Body fat distribution
disease risk, 764–766
cross-sectional and prospective studies, 764–765
gender gap, 766–767
factors influencing, 777–782
environmental interactions, 779–780
genetic influences, 777–779
sex hormones and sexual dimorphism, 780–781, 791–794
stress and hypothalamic arousal mechanisms, 781–782, 794–795
historical aspects, 761–763
measures, 763, 767–770
anthropometric indexes, 767–768
imaging methodologies, 768–770
metabolic profile and, 782–790
blood pressure, 789–790
dyslipidemias, 787–789
glucose intolerance and NIDDM, 785–787
insulin resistance and splanchnic insulin dynamics, 783–785
response to weight loss, 797–798
perspectives, 798–800
regional adipose tissue, 770–777
biologic (metabolic) activity, 775–777
morphology, 773–775
preadipocyte recruitment, 771–773
response to weight loss, 797
skin-fold thickness, 767
waist-to-hip ratio, 767
weight loss and, 797–798
Botulinum neurotoxin, quantal acetylcholine release and, 930–933
Bovine papilloma virus protein E1, DNA replication, 265–266
Bradykinin
response of visceral afferent fibers, 125
vascular large-solute permeability and, 205–206
Buccal ganglion, chaotic behavior (mollusks), 30
2,3-Butanedione monoxime, calcium channel modulation in muscle cells, 444–445

C

Cadmium
effects on sodium-potassium pump, 687
intracellular, inhibition of calcium channels in muscle cells, 405–406
Calcitonin gene-related peptide
corelease with acetylcholine, 949–950
receptor-mediated modulation of calcium channels in muscle cells, 429
Calcium
effects on sodium-potassium pump, 687
extracellular, ectothermic vertebrate heart, 226
extrusion from cell, in ectothermic vertebrate heart, 224
intracellular. *See also* Calcium stores
stimulation and inhibition of calcium channels in muscle cells, 402–405
low, quantal acetylcholine release, estimation of number of quanta released, 941
modulation of NMDA receptor activity, 736
in mutant NMDA receptors, 747–748
quantal acetylcholine release and, 906–914
release, 603–607

T tubule-sarcoplasmic reticulum junction, 60–62
sodium-hydrogen exchange in vascular smooth muscle and, 697–698
sodium-potassium-chloride cotransport in vascular smooth muscle, 706
total, assay, 622–623
Calcium-adenosinetriphosphatase, sarco/endoplasmic reticulum, 597–600
isoforms, tissue-specific expression and modulation, 599–600
kinetics of activity, 597
structure-function relationships, 597–598
Calcium channel(s)
cardiac and smooth muscle L-type channels, 456–457
primary sequence of heart and smooth muscle channels, 457
subunit composition and molecular properties, 456–457
channel structure and subunit composition in muscle cells, 451–457
cardiac and smooth muscle L-type channels, 456–457
oligomeric structure of skeletal muscle L-type channels, 452
subunits of skeletal muscle L-type channels, 452–456
α_1-subunit, 452–455
α_2-subunit, 455
β-subunit, 455–456
γ-subunit, 455–456
extracellular cation modulation in muscle cells, 391–402
current-carrying divalent cations, 394–398
calcium-dependent inactivation, 395–397
concentration-dependent current amplitude, 394–395
ion-dependent gating, 398
mixtures of permanent divalent cations, 397–398
relative current-carrying ability, 394
current-carrying monovalent cations, 398–400
current-suppressing monovalent cations, 400–401
block of L-type channels, 400–401
block of T-type channels, 401
external protons, 402
physiological situation, 391–394
extracellular magnesium, 392
extracellular sodium, 392–394
reversal potentials, 400
intracellular cation modulation in muscle cells, 402–406
inhibition, 405–406
barium, 405
cadmium, 405–406
calcium, 403–405
magnesium, 405
intracellular calcium, 402–405
inhibition, 403–405
stimulation, 403
intracellular protons, 406
intracellular enzymatic cascade regulation in muscle cells, 407–415
adenosine 3′,5′-cyclic monophosphate second messenger system, 407–411
effects on T-type channels, 411
L-type channel subunits and cAMP-dependent phosphorylation, 410–411
modulation of L-type channels, 407–409
modulation of skeletal muscle L-type channels, 409–410
modulation of smooth muscle L-type channels, 410
on physical basis of phosphorylation-induced stimulation, 411
fatty acids and metabolites as second messengers, 414–415
guanosine 3′,5′-cyclic monophosphate second messenger system, 411–413
impact on cAMP-dependent upmodulated activity, 412–413
regulation of basal calcium channel activity, 412
phosphoinositide signaling system, 413–414
diacylglycerol and protein kinase C, 413–414
inositol 1,4,5-trisphosphate, 413
membrane-delimited modulation by G proteins, 431–432
in motor nerve terminals, 905–906
channel classification, 905
channel localization, 906–907
active zones in fast fibers, 906
active zones in slow fibers, 906
consequences of, 907
immunocytochemical localization, 907
toxins for, 907
channels involved in phasic transmitter release, 905–906
receptor-mediated modulation in muscle cells, 415–431
factors affecting receptor-mediated responses, 416–417
cholera toxin, 416
intracellular guanosine 5′-triphosphate, 416–417
nonhydrolyzable guanosine nucleotides, 417
pertussis toxin, 416
functional cycle of G proteins, 415–416
responses to β-adrenergic receptor stimulation, 417–421
responses to α-adrenergic stimulation, 423–425
responses to muscarinic receptor stimulation, 421–423
responses to other receptor agonists, 427–431
angiotensin II, 428
atrial natriuretic peptide, 429–430
calcitonin gene-related peptide, 429
endothelin, 428–429
glucagon, 427–428
histamine, 427
neuropeptide Y, 431
parathyroid hormone, 430–431
serotonin, 431
somatostatin, 431
substance P, 431
thrombin, 430
vasopressin, 431
responses to purinergic receptor stimulation, 425–427
reconstitution and expression in muscle cells, 457–461
expression of functional calcium channels, 458–460
cardiac and smooth muscle channels, 459–460
chimeric calcium channel constructs, 460–461
skeletal muscle channels, 458–459
incorporated cardiac and smooth muscle channels, 458
reconstituted skeletal muscle proteins, 457–458
regulation and modulation in muscle cells, 365–461
alcohols, 446
2,3-butanedione monoxime, 444–445
calcium antagonists and agonists, 442–443
cardiac glycosides, 445
channel classification and notations, 367
channel structure and subunit composition, 451–457
dihydropyridines, phenylalkylamines, and benzothiazipines, 433–441
benzothiazipine binding sites, 441
channel pores and pore-blocking regions, 441
dihydropyridine binding site and modulatory action, 441
dual action of dihydropyridine activators, 438–440
dual action of primary blockers, 434–437. *See also* Calcium channel blockers
modified response of upmodulated channels, 440
phenylalkylamine receptor and blocking action, 441
relation to structural data, 440–441
relative insensitivity of T-type channels, 433–434
diphenylalkylamine blockers, 442–443
dual action of dihydropyridine activators, 438–440
activation by racemic preparations and their stereoisomers, 438–439

block by activating racemates and stereoisomers, 439–440
mechanisms of activation, 439
extracellular cations and, 391–402. *See also* Calcium channel(s), extracellular cation modulation
halothane, 445
heparin and endogenous peptide, 445
intracellular cations and, 402–406. *See also* Calcium channel(s), intracellular cation modulation
membrane-delimited modulation by G proteins, 431–432
methodological considerations, 367–375
experimental preparations and techniques, 367–371
isolated myocytes, 368–370
whole cell microeletrode voltage clamp, 368
whole cell perforated patch-clamp method, 369–370
whole cell ruptured-patch/voltage-clamp/cell-dialysis technique, 368–369
L-type and T-type currents, 371–373
characteristic differences, 372–373
distribution and relative densities, 371–372
multicellular cardiac and smooth muscle preparations, 367–368
relation of single-channel current to whole cell current, 373–375
single-channel patches, 370–371
single channels in lipid bilayers, 371
voltage clamp of skeletal muscle cells, 368
overview and nomenclature, 365–367
phenothiazines and other calmodulin antagonists, 443
receptor-mediated modulation, 415–431
regulation by intracellular enzymatic cascades, 407–415. *See also* Calcium channel(s), intracellular enzymatic cascade regulation
rundown, phosphatases, and proteases, 446–451
phosphatases, 449–450
rundown in patches excised from heart cells, 447–448
calcium concentration, 447
phosphorylation, 447
proteolysis, 447–448
stimulatory G proteins, 447
rundown in patches excised from smooth muscle cells, 448–449
rundown of whole cell current, 446–447
trypsin, pronase, and other proteases, 450–451
sodium channel blockers, 443–444
temperature and, 406–407
tetrandrine, 446
toxins, 444
voltage modulation, 375–391. *See also* Calcium channel(s), voltage modulation
responses to β-adrenergic receptor stimulation
cardiac L-type channels, 417–420
average and unitary current amplitudes, 419
fast gating kinetics, 419
gating current, 420
shifts in gating modes, 419–420
slow gating kinetics, 419
whole cell current changes, 418–419
muscle T-type channels, 421
skeletal muscle L-type channels, 420
smooth muscle L-type channels, 420–421
responses to α-adrenergic stimulation, 423–425
responses to muscarinic receptor stimulation, 421–423
effects on basal calcium channel activity, 421–422
inhibition of cAMP-mediated upmodulated activity, 422–423
responses to purinergic receptor stimulation, 425–427
P_1 purinoceptor stimulation, 425–426
P_2 purinoceptor stimulation, 426–427
temperature modulation, 406–407
single-channel currents, 407
whole cell currents, 406–407
voltage modulation in muscle cells, 375–391
activation of single-channel currents, 376–377
activation of whole cell currents, 375–376
activity-dependent facilitation, 387–390
facilitation after high-voltage pulses, 389–390
facilitation in skeletal muscle fibers, 389
frequency-dependent facilitation in cardiac myocytes, 387–388
frequency-dependent facilitation in smooth muscle myocytes, 388–389
B-type and similar calcium channel currents, 390–391
channel activation, 375–380
channel deactivation, 380
channel inactivation, 380–382
channel reactivation, 382–383
current-voltage relations, 377
discrete modes of gating, 385–387
current status of the modes hypothesis, 387
long-opening mode, 386–387
conditions promoting, 386
incidence in absence of drugs, 386
relation to whole cell currents, 386–387
low and medium activity modes, 386
null quiescent mode, 385–386
facilitation after high-voltage pulses, 389–390
facilitation in skeletal muscle fibers, 389
frequency-dependent facilitation in cardiac myocytes, 387–388
dependence on charge carrier, 388
dependence on pulsating parameters, 387
effects of cAMP-cascade stimulation, 387–388
frequency-dependent facilitation in smooth muscle myocytes, 388–389
L-type current, 388–389
T-type current, 389
gating currents, 378–380
inactivation of T-type currents, 382
mechanism of voltage-dependent inactivation, 382
multiple single-channel conductance levels, 384–385
time-dependent inactivation of L-type currents, 381–382
voltage dependence of L-type current inactivation, 381
voltage shifts related to surface charge screening, 377–378
window currents, 383–384
L-type window current, 383–384
T-type window current, 384

Calcium channel blockers
access to binding sites, 434
block and state-dependent binding, 434–436
channel activation by primary blockers, 437
dihydropyridine blockers, 437
diltiazem, 437
phenylalkylamines, 437
diphenylalkylamine blockers, 442–443
diphenylbutylpiperidine blockers, 443
dual action of primary blockers, 434–437
modification of calcium channel gating, 436–437
activation and inactivation time courses, 436–437
fast channel kinetics, 437
slowed repriming, 437
stabilization of inactivation, 437
newer classes, 443

Calcium current(s)
carotid body chemoreceptor cells from adult animals, 864
in motor nerve terminals, 905–906

Calcium-magnesium-adenosinetriphosphatase
plasma membrane, vascular smooth muscle, 690–693

characteristics, 690–691
effects of calmodulin, 691
effects of cGMP, 691–692
measurement, 690
physiological significance, 692–693
regulation, 691–692
sarcoplasmic reticulum, vascular smooth muscle, 693–696
characteristics, 694–695
measurement, 694
physiological significance, 695–696
regulation, 695
Calcium stores, 595–625
calcium release, 603–607
endo/sarcoplasmic reticulum channels, 603–607
inositol 1,4,5-trisphosphate receptor, 603–607
expression, 606–607
function and regulation, 604–606
molecular structure, 603–604
other mechanisms, 607
ryanodine receptor, 603–607
expression, 606–607
function and regulation, 604–606
molecular structure, 603–604
calcium uptake, 596–601
hydrogen (sodium)-calcium antiporters, 601
mitochondrial calcium electrogenic uniport, 600–601
other mechanisms, 600–601
sarco/endoplasmic reticulum calcium pumps, 597–600
kinetics of sarco/endoplasmic calcium-ATPase activity, 597
sarco/endoplasmic calcium-ATPase isoforms: tissue-specific expression and modulation, 599–600
structure-function relationships, 597–598
calsequestrins and calreticulins, 601–603
cytology, 607–617
endoplasmic reticulum, 608–614
endosomes and lysosomes, 615–616
Golgi complex, 615
mitochondria, 616
nucleus, 616–617
secretion granules and vesicles, 615
endoplasmic reticulum, 608–614
calcium-specialized endoplasmic subcompartments in nonmuscle cells: calciosome concept, 611–613
cytosolic free calcium oscillators, continuity, contiguity, and molecular heterogeneity in endoplasmic reticulum, 613–614
sarcoplasmic reticulum, 610–611
endosomes and lysosomes, 615–616
functional heterogeneity, 617–621
rapidly exchanging calcium pools, 617–621
slowly exchanging calcium pools, 621
Golgi complex, 615
methods for in situ study of organelle calcium, 621–625
free ionized calcium, 623–625
chimeric aequorins as intraorganelle calcium probes, 624–625
fluorescent calcium indicators, 623–624
total calcium, 622–623
electron energy loss spectrometry, 623
electron probe X-ray analysis, 622–623
electron spectroscopy imaging, 623
secondary ion mass spectrometry microscopy, 622
mitochondria, 616
nucleus, 616–617
overview, 595–596
rapidly exchanging calcium pools, 617–621
calcium cycling and its energetics, 619
calcium release-calcium influx connection, 619–620
cytosolic free calcium oscillations and waves, 620–621
thapsigargin-, inositol 1,4,5-trisphosphate-, and ryanodine-sensitive pools, 617–619
secretion granules and vesicles, 615
slowly exchanging calcium pools, 621
Calcium transient, in ectothermic vertebrate heart, 224
Calmodulin, effects on calcium-magnesium-adenosinetriphosphatase, 691
Calmodulin antagonists, calcium channel modulation in muscle cells, 443
Calreticulin, calcium storage, 601–603
Calsequestrin, calcium storage, 601–603
Cancer, obesity and, 764
Capillary hydrostatic pressure, transvascular transport of macromolecules
coupling of solute flux to transcapillary volume flow in heteroporous membranes, 185–186
heteroporosity effects on Starling fluid balance, 186–187
Carbohydrate(s), peroxidation, 147–148
Carbohydrate metabolism, muscle fatigue and, 74–78
blood glucose, 76–77
historical perspective, 74–75
muscle glycogen, 76–76
reduced carbohydrate oxidation and, 77–78
Carbon dioxide
ectothermic vertebrate heart, 240–241
partial pressure
acidosis and contractility of ectothermic vertebrate heart, 241–242
arterial, peripheral chemoreceptor function and, 545
Carcinogenesis, cellular defenses in, 154–155
Cardiac glycosides, calcium channel modulation in muscle cells, 445
Cardiac output, carotid chemoreceptor stimulation and, 560
Cardiac receptors, interactions with peripheral chemoreceptors, 573
Cardiopulmonary receptors, interactions with peripheral chemoreceptors, 572–573
Cardiovascular disease
body fat distribution and, 765–766, 787
obesity and, 764
Cardiovascular reflexes
central pathways mediating, 348–350
chemoreceptor reflexes. *See* Peripheral chemoreceptors
Cardiovascular system
afferent inputs, 338
calcium channel regulation and modulation in cardiac muscle cells, 365–461. *See also* Calcium channel(s), regulation and modulation
chaos in the heart, 26–28
dynamics of cardiac cells, 26–27
low-dimensional chaos in intact heart, 27–28
energy metabolism and contractility in ectothermic vertebrate heart. *See* Ectothermic vertebrate heart
regulation
functional organization of central pathways. *See* Central cardiovascular pathways
peripheral chemoreceptors and. *See* Peripheral chemoreceptors
sensory innervation, 100–104
arteries, 103
blood vessels, 103–104
cardiac pain, 102–103
cardiac sensations, 100–101
heart, 101–102
veins, 103–104
Carotenoids, antioxidant properties, 144

Carotid body
biochemical properties, 841–846
neurotransmitter metabolism, 843–846
oxygen consumption and energy production, 841–843
chemoreceptors. *See* Carotid body chemoreceptors
efferent control of carotid body output, 861–862
gross anatomy, 830
histochemistry and immunochemistry, 835–841
carbonic anhydrase, 839
carotid body nerve endings, 839–841
neural crest markers, 835
neurotransmitters in chemoreceptor cells, 835–839
histology, 830–831
innervation, 830
ultrastructure, 833
neurotransmitter metabolism, 843–846
acetycholine, 846
catecholamines, 844–846
opioid peptides, 846
substance P, 846
oxygen consumption and energy production, 841–843
carotid body oxygen consumption, 842–843
carotid body tissue Po_2, 843
oxygen delivery to carotid body and carotid body blood flow, 841–842
structural organization, 830–841
ultrastructure, 831–835
blood vessels and their innervation, 833–835
chemoreceptor (type I) cells, 831–832
nerve endings in cell clusters, 833
sustentacular (type II) cells, 832–833
vascularization, 830
ultrastructure, 833–835
Carotid body chemoreceptors, 829–877. *See also* Peripheral chemoreceptors
carotid body output and activity in carotid sinus nerve, 851–861
response to hypercapnia and low pH, 855–856
response to hypoxia, 853–855
response to metabolic poisons, 857–858
response to neurotransmitters, their agonists, and their antagonists, 858–861
response to temperature and osmolarity, 856–857
resting carotid sinus nerve activity, 851–853
chemoreceptor (type I) cells
acetylcholine release, 847–848
dopamine release and control, 848–851
electrical properties, 862–865
excitability, 862
ionic currents in cells from adult animals, 863–864
calcium currents, 864
potassium currents, 863–864
sodium currents, 863
ionic currents in cells of neonatal animals, 864–865
neurotransmitter release, 846–851
neurotransmitters in, immunohistochemistry, 835–839
norepinephrine release and control, 848–851
transduction of natural stimuli in, 865–874
ultrastructure, 831–832
input-output relationships, 846–862
carotid body output and activity in carotid sinus nerve, 851–861
chemoreceptor cell output and neurotransmitter release, 846–851
acetylcholine release, 847–848
dopamine and norepinephrine release and control, 848–851
other neurotransmitters, 851
efferent control of carotid body output, 861–862
introduction, 829–830
neurotransmission at chemoreceptor cell-sensory nerve ending synapse, 874–877
acetylcholine and, 876
dopamine and, 874–876
norepinephrine and, 876
opioid peptides and, 877
prostaglandin E_2 and, 876–877
response to hypercapnia and low pH, 855–856
response to hypoxia, 853–855
response to metabolic poisons, 857–858
response to neurotransmitters, their agonists, and their antagonists, 858–861
acetylcholine, 858
dopamine, 858–860
5-hydroxytryptamine, 861
norepinephrine and epinephrine, 860
opioid peptides, 861
substance P, 861
response to temperature and osmolarity, 856–857
role in brain stem defense areas, 566–569
second messengers and chemoreceptor cell function, 873–874
adenosine 3′,5′-cyclic monophosphate, 873
guanosine 3′,5′-cyclic monophosphate, 873
nitric oxide, 873
phospholipase C-derived messengers, 873
prostaglandins, 873
stimulation, primary cardiovascular response, 559–566
transduction of natural stimuli in, 865–874
high-Pco_2 low-pH transduction, 869–872
low-Po_2 transduction, 865–869
second messengers and chemoreceptor cell function, 873–874
Carotid sinus nerve
response to hypercapnia and low pH, 855–856
response to hypoxia, 853–855
response to metabolic poisons, 857–858
resting activity, carotid body output and, 851–853
Catalase, antioxidant defense, 145
Catecholamines
body fat distribution and, 782
carotid body metabolism, 844–846
release, carotid body chemoreceptor output and, 848–851
Caudal raphe nuclei, cardiovascular sympathetic premotor neurons, 335–336
Cellular defense systems, 139–162
in aging process, 151–153
age-related alterations and damage, 152–153
correlation between defense capacity and longevity, 152
antioxidant defense systems, 142–146. *See also* Antioxidant defense systems
in atherosclerosis, 153–154
in carcinogenesis, 154–155
in diabetes mellitus, 155–156
in disease, 153–156
Cellular physiology, intracellular calcium stores, 595–625. *See also* Calcium stores
Central cardiovascular pathways, 323–351
autonomic neurons controlling cardiovascular effectors, 324–328
sympathetic preganglionic neurons, 324–328
vagal preganglionic neurons, 324
brain regions controlling cardiovascular sympathetic premotor neurons, 340–346
amygdala, 345
anteroventral third ventricle region, 345
area postrema, 341–342

caudal ventrolateral medulla, 340–341
cerebellar nuclei, 342
cortical regions, 346
forebrain nuclei, 344–346
hypothalamus, lateral and posterior regions, 344–345
locus ceruleus, 343
medullary lateral tegmental field, 341
midbrain periaqueductal gray, 343–344
parabrachial complex, 342–343
septal nuclei, 346
cardiovascular sympathetic premotor neurons, 328–338
A5 noradrenergic cell group, 336
brain regions controlling, 340–346
caudal raphe nuclei, 335–336
paraventricular nucleus, 337
rostral ventrolateral medulla, 328–334
Afferent inputs, 331
chemical properties, 333–334
electrophysiological properties, 330–331
origin of spontaneous activity, 334
outputs, 329–330
pharmacological properties, 331–333
rostral ventromedial medulla, 335
summary, 337–338
central processing of cardiovascular afferent inputs, 338–340
nucleus of solitary tract, 338–340
efferent outputs, 340
modulation of signal transmission, 339–340
neurotransmitters of primary afferent fibers, 338–339
sites of termination of primary afferent fibers, 338
sources of inputs, 338
functional considerations, 346–350
baroreceptor reflex, 347–348
cardiovascular reflexes, 348–350
specificity of central control of sympathetic vasomotor neurons, 346–347
introduction, 323
overview, 323–324
sympathetic preganglionic neurons, 324–328
chemical properties, 325–326
cytoarchitecture, 324–325
functional properties, 326
location with respect to target organs, 325
morphology, 325
neurotransmitters controlling, 327
synaptic inputs, 326–327
Central chemoreceptors, interactions with peripheral chemoreceptors, 575
Central nervous system
functional organization of central cardiovascular pathways. *See* Central cardiovascular pathways
sensory innervation of intracranial structures, 122–123
Cerebellar nuclei, control of cardiovascular sympathetic premotor neurons, 342
Cerebellorubrospinal system
anatomic relations, 510–514
cerebellar nuclear projections to red nucleus, 511
cerebrocortical projections to red nucleus, 511–512
precerebellar nuclei contributions to recurrent brain stem pathways, 512
rubrospinal pathway, 510–511
sensory projections to red nucleus, 512–513
summary, 513–514
cellular properties and neurotransmitters relevant to information processing, 520–526
cerebellar nuclear cells, 522–523
electrophysiology and neurotransmitters, 522–523
Purkinje cells, 523–525
calcium dynamics in optically recorded Purkinje neurons, 524
conjunctive activation of parallel and climbing fibers, 525
electrophysiology, 523–525
intrinsic determinants of firing behavior, 523–524
responses to climbing and parallel fiber synaptic inputs, 524–525
red nucleus neurons, 520–522
intrinsic properties and synaptic responses, 520–521
neurotransmitters and receptor pharmacology, 521–522
information processing in nucleus interpositus, 516–517
responses to cutaneous inputs, 517
velocity signals, 516–517
mechanisms for generation of motor commands in cerebellorubral circuits: positive feedback in distributed limb premotor network, 529–533
conclusions, 533
in vitro model system to study cerebellorubral circuits, 530–531
studies in cat, 529–530
theory of motor command generation, 531–533
motor function, 526–529
action of rubral commands on spinal cord and musculature, 526–529
rubral signals to muscles, 527–529
synaptic inputs of rubrospinal tract projections on spinal targets, 526–527
introduction, 509–510
mechanisms for generation of motor commands in cerebellorubral circuits: positive feedback in distributed limb premotor network, 529–533
rubral signals to muscles, 527–529
effects of lesions on motor behavior, 527–528
output organization of red nucleus and cerebellum, 528–529
signal flow revealed by single-unit recordings, 514–520
climbing and mossy fibers, 518–519
contrasting signals of mossy fibers, 518–519
signals of somatic events transmitted by climbing fibers, 518
gating of sensory input during movement, 519
inhibition of sensory responses in inferior olive, 519
suppression of somatosensory input to red nucleus, 519
nuclear and Purkinje cells, 516–518
information processing in nucleus interpositus, 516–517
relationship between Purkinje and nuclear cells, 517–518
signals in Purkinje cells of intermediate cerebellum, 517
red nucleus, 514–516
activity in red nucleus during rhythmical movement, 515–516
movement parameters encoded in red nucleus, 514–515
sensory signals to red nucleus, 516
synaptic inputs of rubrospinal tract projections on spinal targets, 526–527
interneurons, 526–527
presynaptic inhibition, 527
Cerebral circulation, carotid chemoreceptor stimulation and, 563–565
Cerebral cortex, control of cardiovascular sympathetic premotor neurons, 346
Cerebrovascular system, sensory innervation, vascular mechanisms of headache, 104
Ceruloplasmin, in free radical modulation, 150
C-fiber receptors. *See* J-receptors
Chaos, 1–41
basic principles of theory of dynamic systems, 8–26. *See also* Dynamic systems

cardiac applications, 26–28
dynamics of cardiac cells, 26–27
low-dimensional chaos prevails in intact heart, 27–28
deterministic
in excitable cell assemblies, 1–41
sinusoidally forced squid membrane, 5–6
dynamics of renal blood flow regulation. *See* Kidney, blood flow regulation
homeostasis and, 3, 6–8
introduction
chaotic homeostasis, 6–8
sinusoidally forced squid membrane, 5–6
universality of chaos in complex neuronal networks, 2–5
neuroscience applications, 28–40
chaos in cell assemblies and brain structures (animals), 30–33
buccal ganglion of mollusks, 30
dimensional evaluations of specific cortical structures in cats, 32–33
olfactory system of rabbit, 30–32
precentral and postcentral gyrus of squirrel monkeys, 30
chaos in electroencephalogram and magnetoencephalogram, 33–36
dynamics of isolated neuron, 28–30
giant axons of squid (*Doryteuthis bleekeri*), 29
giant internodal cell of freshwater algae (*Nitella flexilis*), 28–29
giant neurons in isolated esophageal ganglion of marine pulmonate mollusk (*Onchidium verruculatum*), 29
pond snail (*Lymnaea stagnalis*), 29
Hebbian cell assemblies, 38–40
pathological processes investigated by tools derived from theory of dynamic systems, 36–38
tubuloglomerular feedback, chaotic tubular pressure fluctuations in hypertension, 655–657
chaos or noise, 655–656
possible causes of transition to chaos, 656
primary or secondary changes, 656–657
universality of chaos in complex neuronal networks, 2–5
analyzing time series, 4–5
chaos and homeostasis, 3
effects of weak perturbations, 3–4
nonlinear systems theory and relation between normal and abnormal functioning, 4
sensitive dependence on initial conditions, 2–3
Chemotherapy, inhibitors of DNA replication enzymes, 278–297
Chloride, early distal chloride activity, in tubuloglomerular feedback, 650–651
Chloride-bicarbonate exchange, vascular smooth muscle, 708–710
Chloride channels
ClC family, 815–820
ClC-0 channel, 815–816
ClC-1 channel, 816–818
ClC-2 channel, 818–819
ClC-K channels, 819–820
common properties, 820
I_{Cln}, volume-activated chloride channel or regulator, 820–821
molecular physiology, 813–827
ClC family, 815–820
introduction, 813–815
P-glycoprotein (mdr1), 822
phospholemman, volume-activated chloride channel or regulator, 821–822
voltage-gated, molecular physiology, 813–827
Cholera toxin, receptor-mediated modulation of calcium channels in muscle cells, 416
Choroid plexus, glucose transport in, 1015
Circulatory system, macromolecular transport across microvascular walls, 163–219. *See also* Transvascular transport
Colloid oncotic pressure, plasma, heteroporosity effects on Starling fluid balance, in transvascular transport of macromolecules, 187–188
Colon
pain, 114–115
sensations from, 113
sensory innervation, 113–114
parasympathetic afferent fibers, 114
sympathetic afferent fibers, 114
Computed tomography (CT scan), body fat distribution, 768–769
Contractility
ectothermic vertebrate heart. *See also* Ectothermic vertebrate heart
in acidotic conditions, 239–245
hypoxia and, 235–239
temperature and, 245–249
skeletal muscle. *See* Skeletal muscle
Copper, in free radical modulation, 149–150
Coronary circulation, carotid chemoreceptor stimulation and, 560–561
Cortisol, metabolism, in obesity, 764

D

Dense vesicles, quantal acetylcholine release, 949
Deoxyribonucleic acid. *See* DNA
Deoxyribonucleoside triphosphate, biosynthesis
de novo purine and pyrimidine nucleotide biosynthesis, 275–276
enzymes in, inhibitors of, 278–281
salvage pathways of nucleotide biosynthesis, 276–277
Depression, quantal acetylcholine release, 939–940, 962
Desipramine, block of recombinant NMDA receptors, 748
Dextran, neutral, vascular large-solute permeability and, 208
Diabetes mellitus
cellular defenses in, 155–156
non-insulin-dependent
body fat distribution and, 764–766
glucose intolerance and body fat distribution, 785–787
obesity and, 763–764
quantal acetylcholine release in, 955
sodium-glucose transport in, 1017–1018
Diacylglycerol, calcium channel regulation in muscle cells, 413–414
2′,3′-Dideoxyribonucleosides
inhibition of DNA polymerases, 286
inhibition of HIV reverse transcriptase, 288–291
Diet, dependence of SGLT1 expression, 1015–1016
Dihydropyridines, modulation of calcium channels in muscle cells, 433–441. *See also* Calcium channel blockers
Diltiazem, 437
Diphenylalkylamine blockers, calcium channel modulation in muscle cells, 442–443
Diphenylbutylpiperidine blockers, calcium channel modulation in muscle cells, 443
Diuretics, oscillations in tubuloglomerular feedback and, 650
Diving, peripheral chemoreceptors in, 580
DNA, free radical-induced oxidative damage, 148
DNA replication, 259–297
actors at eukaryotic replication fork, 261–262
basic rules, 260–261
chromatin and, 273–275
deoxyribonucleoside triphosphate biosynthesis, 275–277
de novo purine and pyrimidine nucleotide biosynthesis, 275–276
salvage pathways of nucleotide biosynthesis, 276–277
enzymes and proteins at replication fork, functional role, 261–262
inhibitors of DNA replication enzymes, 278–297
herpesvirus thymidine kinase, 281–283

drugs suppressing, latent phase, 282-283
properties and selectivity of clinically effective antiherpetic drugs, 281-282
sterospecificity, 283
inhibitors of cellular and virus-encoded DNA polymerases, 283-288
active-site directed inhibitors, 287-288
nucleoside analogues modified in base ring, 284-285
nucleoside analogues modified in sugar moiety, 285-287
acyclic nucleoside analogues, 286-287
arabinonucleosides, 285-286
carbocyclic nucleoside analogues, 287
2′,3′-dideoxyribonucleosides, 286
inhibitors of DNA ligases, 295-297
inhibitors of DNA topoisomerases, 293-295
inhibitors of enzymes involved in deoxyribonucleoside triphosphate synthesis, 278-281
inhibitors of HIV reverse transcriptase, 288-293
acyclic nucleoside phosphonates, 291-292
carbocyclic nucleosides, 291
2′,3′-dideoxynucleosides, 288-291
nonsubstrate analogues, 292-293
substrate analogues, 288-292
initiation of
initiator proteins, 265-266
origins of replication, 264-265
where and how, 263-266
initiator proteins, 265-266
bacteriophage λ O protein, 265
bovine papilloma virus protein E1, 265-266
Escherichia coli DnaA protein, 265
herpes simplex virus-1 UL9 protein, 266
human RIP60 protein, 266
Saccharomyces cerevisiae origin recognition complex, 266
simian virus 40 large T antigen, 265
model systems, 262-263
aryotes, 262
viruses, 262-263
origins of, 2642-265
physiological importance, 259-260
proteins and enzymes at replication fork, 266-275
chromatin and, 273-275
DNA helicases, 266-267
DNA ligases, 271-272
DNA polymerase auxiliary proteins, 269-270
alpha-associated factor, 270
proliferating cell nuclear antigen, 269
replication factor C, 269-270
DNA polymerases, 267-268
DNA primases, 268
DNA topoisomerases, 270-271
how they might function together, 272-273
single-stranded DNA binding proteins, 268-269

Dopamine. *See also* Catecholamines
carotid body chemoreceptor response to, 858-860
neurotransmission at carotid body chemoreceptor cell-sensory nerve ending synapse and, 874-876
release and control, carotid body chemoreceptor output and, 848-851

Dynamical systems theory. *See* Dynamic systems

Dynamic systems
application to physiological time series, 24-26
deterministic vs. stochastic processes, 24-25
stationary and short-term changes in dimension, 25
use of filters and comparison with white and colored noise, 25-26
attractors, 638-640
quantitative methods for detection of strange attractors, 642-644
attractors and differential equations, 11-12
basic principles, 8-26
cardiac cells, 226-27
correlation dimension, 17
Grassberger-Procaccia correlation dimension, 22-23
methods for calculating, 22-24
point D2 correlation dimension, 18, 23-24
pointwise dimension, 23
selection of r, 24
difference equations, 8-11
dynamical analysis of input-output data, 644-647
linear systems, 644-645
linear systems identification, 645
nonlinear systems identification, 645-647
evolution of a system, 19-22
entropy, 19-20
Lyapunov exponents, 20-22
fractal dimension, metric entropy, and spectrum of Lyapunov exponents characterize attractors, 15-22
Lorenz and Rössler: famous attractors and differential equations, 11-12
measuring geometric structure, 15-19
capacity dimension, 15-16
correlation dimension, 17
Hausdorff-Besicovitch dimension, 16-17
information dimension, 17
point D2 correlation dimension, 18
pointwise dimension, 17-18
relationship of dimensional measures, 18-19
methods for characterizing, 640-642
power spectra, 641
state space reconstruction, 641-642
Poincaré sections and return map: linking differential and difference equations, 13-15
pointwise dimension, 17-18, 23
power spectra, 641
properties, 638-647
attractors, 638-640
dynamical systems, 638
quantitative methods for detection of strange attractors, 642-644
attractor dimension, 642-643
Lyapunov exponents and entropy, 643
nonlinear forecasting and predictability of chaotic systems, 643
surrogate data analysis, 643-644

Dyslipidemia, body fat distribution and, 787-789

E

Ectothermic vertebrate heart
amphibians
adaptation to chronic low-temperature exposure above freezing, 248
heart anatomy and vascularization, 222
in situ heart performance, 223
hypoxia and, 226-227
metabolism in isolated preparations, hypoxia and, 229
anatomy and vascularization, 222
cellular features, 223-226
active calcium extrusion, 224
excitation and calcium transient, 224
extracellular calcium, 226
mitochondria, 225
sarcolemma, 225-226
sarcoplasmic reticulum, 224-225
surface-to-volume ratio, 223-224
contractility

acidosis and hypoxia in combination, 244
in acidotic conditions, 239–245
depression of contractility, 242
influence of alterations in P_{CO_2} and bicarbonate, 241–242
recovery of contractility during acidosis, 242
regulation of force, 244
in hypoxia, 236–239
conclusions, 239
contractile proteins, inorganic phosphate, and adenosine 5′-diphosphate in, 236–237
cytoplasmic energy state and, 236
depressed metabolism and, 239
excitation-contraction coupling, 237–239
intracellular pH and, 237
regulation of, 239
temperature and, 245–249
energy metabolism and contractility, 221–258. *See also* "contractility"
animals of study and their ecophysiology, 221–222
cellular features, 223–226
impact of oxygen-limiting conditions, 226–239
introduction, 221–226
objectives of review, 221
temperature and, 244–249
acute temperature transitions above freezing, 245–246
chronic low-temperature exposure above freezing, 246–249
low-temperature exposure of freeze-tolerant frogs, 249
enzyme activity, temperature and, 246
excitation-contraction coupling
in hypoxia, 237–239
temperature and, 245–246
fish
adaptation to chronic low-temperature exposure above freezing
Antarctic teleosts, 248
nonpolar teleosts, 247
heart anatomy and vascularization, 222
in situ heart performance, 222–223
hypoxia and, 226
metabolism in isolated preparations, hypoxia and, 229
metabolism in vivo, hypoxia and, 228
impact of oxygen-limiting conditions
conclusion, 239
contractile proteins, inorganic phosphate, and adenosine 5′-diphosphate, 236–237
contractility and intracellular pH, 237
contractions under depressed metabolism, 239
cytoplasmic energy state and contractility, 236
determinants of calcium-activated force, 236–239
excitation-contraction coupling, 237–239
importance of myoglobin, 227–228
in situ cardiac performance, 226–227
metabolic control at enzyme level, 232–236
ectotherms vs. endotherms, 236
glycogen phosphorylase, 232–233
hexokinase, 233
lactate dehydrogenase, 235
phosphofructokinase, 233–235
pyruvate kinase, 235
relative maximal enzyme activity levels, 232
metabolic rates and high-energy phosphates, 228–231
metabolism in isolated preparations, 229–230
metabolism in vivo, 228–229
metabolic regulation in relationship to performance, 235–236
regulation of hypoxic contractility, 239
in situ heart performance, 222–223
acute temperature transitions above freezing and, 245
amphibians, 223
comparison with endotherms, 223
fish, 222–223
hypoxia and, 226–227
reptiles, 223
intracellular pH
acidosis and, 241
contractility under hypoxia and, 237
metabolic control at enzyme level, hypoxia and, 232–236
metabolism in isolated preparations
hypoxia and, 229–230
temperature and, 246
metabolism in vivo, hypoxia and, 228–229
range of hydrogen, carbon dioxide, and bicarbonate, 240–241
air-breathing fish and amphibians, 240
obligate water breathers, 240
reptiles, 240–241
reptiles
adaptation to chronic low-temperature exposure above freezing, 248–249
heart anatomy and vascularization, 222
in situ heart performance, 223
hypoxia and, 227
metabolism in isolated preparations, hypoxia and, 229–230
metabolism in vivo, hypoxia and, 228–229
Electroencephalogram, chaos in, 33–36
Electron energy loss spectrometry, organelle calcium, 623
Electron spectroscopy, organelle calcium, 623
Endocytosis, quantal acetylcholine release, 938–939
Endogenous peptide, calcium channel modulation in muscle cells, 445
Endoplasmic reticulum, calcium stores, 608–614
calcium-specialized endoplasmic subcompartments in nonmuscle cells: calciosome concept, 611–613
cytosolic free calcium oscillators, continuity, contiguity, and molecular heterogeneity in endoplasmic reticulum, 613–614
sarcoplasmic reticulum, 610–611
Endosomes, calcium storage, 615
Endothelin
receptor-mediated modulation of calcium channels in muscle cells, 428–429
sodium-potassium-chloride cotransport in vascular smooth muscle, 707
End-plate substances, short-term regulation of quantal acetylcholine release, 952–953
Energy metabolism, ectothermic vertebrate heart, 221–258. *See also* Ectothermic vertebrate heart
Entropy, 19–20, 643
Enzyme(s)
antioxidant scavenging enzymes, 145–146
in DNA replication, 261–262. *See also* DNA replication, enzymes and proteins at replication fork
ectothermic vertebrate heart, temperature and, 246
lipolytic, antioxidant defense, 146
metabolic control in ectothermic vertebrate heart, hypoxia and, 232–236
proteolytic, antioxidant defense, 146
Epilepsy, investigation by tools derived from theory of dynamic systems, 36–37
Epinephrine. *See also* Catecholamines
carotid body chemoreceptor response to, 860
***Escherichia coli* DnaA protein,** DNA replication, 265
Esophagus
pain, 106, 107
sensations from, 106

sensory innervation, 106–107
sympathetic afferent fibers, 106–107
vagal afferent fibers, 106
Exercise
intensity
alterations in muscle high-energy phosphates, 72
muscle fatigue and, 51
peripheral chemoreceptors in, 580
synaptic efficacy and, 954
Extremity(ies), circulation, carotid chemoreceptor stimulation and, 561

F

Facial receptors, interactions with peripheral chemoreceptors, 573
Facilitation
calcium channel currents in cardiac myocytes, 387–388
calcium channel currents in smooth muscle myocytes, 388–389
quantal acetylcholine release, 917–918, 919–920, 958
Fatigue, skeletal muscle. *See* Muscle fatigue
Fatty acids, free, enhanced flux in abdominal obesity, 790–791
Feedback, tubuloglomerular. *See* Kidney, tubuloglomerular feedback
Feedback regulation, quantal acetylcholine release, 962
Ferritin, in free radical modulation, 150
Fish, heart metabolism and contractility. *See* Ectothermic vertebrate heart
Fluid absorption, intestinal sodium-glucose cotransport in, 995–996
Fluorescent calcium indicators, 623–624
Forebrain nuclei, control of cardiovascular sympathetic premotor neurons, 344–346
Fractal dimension
capacity dimension, 15–16
correlation dimension, 17
Hausdorff-Besicovitch dimension, 16–17
point D2 correlation dimension, 18
pointwise dimension, 17–18
relationship of dimensional measures, 18–19
Free radicals
biological sources, 141–142
cellular damage from, 146–148
carbohydrate peroxidation, 147–148
lipid peroxidation, 147
modification of genomic and cellular structure, 148
oxidative protein damage, 146–147
cellular defenses against, 139. *See also* Cellular defense systems
characteristics, 140
chemistry, 140–141
free radical theory of aging, 151–152
hydrogen peroxide, 141
hydroxyl radicals, 140–141
modulation of activity
ceruloplasmin in, 150
copper in, 149–150
ferritin in, 150
iron in, 149–150
metal ions in, 149–151
selenium in, 150–151
transferrin in, 150
oxidative threats, 140–142
defense systems against, 142–146. *See also* Antioxidant defense systems
reactivity of, 140
superoxide radical, 140

G

Gastrointestinal tract
intestinal sodium-glucose cotransport in fluid absorption, 995–996
microvascular protein transport at low and high transvascular filtration rates, 200–201
sensory innervation, 106–115
colon and rectum, 113–115
esophagus, 106–107
liver, biliary system, and pancreas, 109–111
small intestine, 111–113
stomach, 107–109
SGLT1 from human intestine (ileum), 999
Gender, obesity-related disease and, 766–767
Genetics
abdominal obesity, 795–797
body fat distribution, 777–779
NMDA receptor gene families, 725–726
structure and splice variants of NMDAR1, 726–727
structure and splice variants of NMDAR2, 727
SGLT1 and SGLT2 genes, 1020–1021
chromosome localizations and genetic structures, 1020
inherited defects in sodium-glucose cotransport, 1020–1021
Glomerular capillaries, microvascular protein transport at low and high transvascular filtration rates, 201–202
Glucagon, receptor-mediated modulation of calcium channels in muscle cells, 427–428
Glucocorticoids
body fat distribution and, 782
sodium-hydrogen exchange in vascular smooth muscle and, 700
Glucose intolerance, body fat distribution and, 785–787
Glucose transporters
facilitated, 994
introduction, 993–994
transepithelial hexose transport, 994–995
Glutamate, NMDA receptor activation, 729–731
Glutathione, antioxidant properties, 144
Glutathione peroxidase, antioxidant defense, 145–146
Glycerotoxin, quantal acetylcholine release and, 935
Glycine, NMDA receptor activation, 729–731
Glycogen, skeletal muscle, fatigue and, 75–76, 82–83
Glycogen phosphorylase, ectothermic vertebrate heart, hypoxia and, 232–233
Glycolysis, skeletal muscle, pH and, 69–70
Golgi complex, calcium storage, 615
Gonadal dysfunction, obesity and, 764
G proteins
functional cycle, 415–416
modulation of calcium channels in muscle cells
membrane-delimited modulation, 431–432
receptor-mediated modulation, 415–416
Grassberger-Procaccia correlation dimension, 22–23
Growth factors
sodium-hydrogen exchange in vascular smooth muscle and, 699–700
sodium-potassium-chloride cotransport in vascular smooth muscle, 707
Guanine nucleotide-binding proteins. *See* G proteins
Guanosine 3′,5′-cyclic monophosphate
carotid body chemoreceptor cell function and, 873–874
effects on calcium-magnesium-adenosinetriphosphatase
plasma membrane, 691
sarcoplasmic reticulum, 695
sodium-potassium-chloride cotransport in vascular smooth muscle, 706–707
Guanosine 3′,5′-cyclic monophosphate second messenger system, modulation of calcium channels in muscle cells, 411–413

impact on cAMP-dependent upmodulated activity, 412–413
regulation of basal calcium channel activity, 412
Guanosine nucleotides, nonhydrolyzable, receptor-mediated modulation of calcium channels in muscle cells and, 416
Guanosine 5′-triphosphate, intracellular, receptor-mediated modulation of calcium channels in muscle cells, 416–417

H

Halothane, calcium channel modulation in muscle cells, 445
Hausdorff-Besicovitch dimension, 16–17
Headache, vascular, 103
Heart. *See* Cardiovascular system
Heart rate, carotid chemoreceptor stimulation and, 559–560
Hebbian cell assemblies, 38–40
Helicases, in DNA replication, 266–267
Hemicholinium-3, quantal acetylcholine release, estimation of number of quanta released, 942
Hemodilution, transvascular transport of macromolecules, coupling of solute flux to transcapillary volume flow in heteroporous membranes, 185–186
Hemorrhage, peripheral chemoreceptors in, 581–584
Heparin
calcium channel modulation in muscle cells, 445
sodium-hydrogen exchange in vascular smooth muscle and, 700
Herpes simplex virus-1 UL9 protein, DNA replication, 266
Herpesvirus thymidine kinase, 281–283
drugs suppressing, latent phase, 282–283
properties and selectivity of clinically effective antiherpetic drugs, 281–282
stereospecificity, 283
Heteroporous system. *See* Transvascular transport, two-pore (heteroporous) system
Hexokinase, ectothermic vertebrate heart, hypoxia and, 233
Hexose transport, transepithelial, 994–995
Hippocampus, chaotic behavior, dimensional evaluations in cats, 32–33
Histamine
allosteric regulation of NMDA receptors, 731–733
receptor-mediated modulation of calcium channels in muscle cells, 427
vascular large-solute permeability and, 205–206
Histamine receptor, stimulation, calcium channel modulation in muscle cells, 427
Histochemistry, carotid body carbonic anhydrase, 839
Homeostasis, chaos and, 3, 6–8
Hormones
control of intracellular free magnesium concentration, 307
control of renal magnesium handling. *See* Magnesium transport, hormonal influences
Human immunodeficiency virus (HIV) reverse transcriptase, inhibitors of, 288–293
acyclic nucleoside phosphonates, 291–292
carbocyclic nucleosides, 291
2′,3′-dideoxyribonucleosides, 288–291
nonsubstrate analogues, 292–293
substrate analogues, 288–292
Human RIP60 protein, DNA replication, 266
Hydrogen ion. *See also* pH
ectothermic vertebrate heart, 240–241
Hydrogen peroxide, 141
Hydrogen (sodium)-calcium antiporters, 601
Hydroxyl radicals, 140–141
5-Hydroxytryptamine
carotid body chemoreceptor response to, 861
receptor-mediated modulation of calcium channels in muscle cells, 431
vascular large-solute permeability and, 205–206
Hypercapnia, carotid body chemoreceptor response to, 855–856
Hyperinsulinemia, obesity and, 764
Hyperlipidemia, body fat distribution and, 787–789
Hypertension
chaotic renal tubular pressure fluctuations in, 655–657
chaos or noise, 655–656
possible causes of transition to chaos, 656
primary or secondary changes, 656–657
myogenic response in renal microvasculature and, 664
renal blood flow autoregulation in, 672
Hypocapnia, peripheral chemoreceptor function and, 552–553
Hypothalamic arousal mechanisms, body fat distribution and, 782, 794–795
Hypothalamus, lateral and posterior regions, control of cardiovascular sympathetic premotor neurons, 344–345
Hypoxia
carotid body chemoreceptor response to, 853–855
ectothermic heart metabolism and contractility, 226–239. *See also* Ectothermic vertebrate heart
response of visceral afferent fibers, 125
systemic, peripheral chemoreceptors in, 577–580

I

$I_{Cl_{vol}}$, volume-activated chloride channel or regulator, 820–821
Immunohistochemistry
carotid body nerve endings, 839–841
neural crest markers in carotid body, 835
neurotransmitters in carotid body chemoreceptor (type I) cells, 835–839
Inositol 1,4,5-trisphosphate
calcium channel regulation in muscle cells, 413
rapidly exchanging calcium pools, 618–619
sodium-potassium-chloride cotransport in vascular smooth muscle, 706
Inositol 1,4,5-trisphosphate receptor
calcium release, 603–607
cellular expression, 606–607
function and regulation, 604–606
molecular structure, 603–604
Insular cortex, control of cardiovascular sympathetic premotor neurons, 346
Insulin metabolism, splanchnic, body fat distribution and, 783–785
Insulin resistance, body fat distribution and, 783–785
Intensity theory, peripheral encoding of noxious events, 100
Intestine, large. *See* Colon
Intestine, small
pain, 111, 113
sensations from, 111
sensory innervation, 111–113
recordings from mesenteric nerves, 112–113
sympathetic afferent fibers, 112
vagal afferent fibers, 112
Ionic current(s). *See also specific channels/currents*
carotid body chemoreceptor cells from adult animals, 863–864
carotid body chemoreceptor cells of neonatal animals, 864–865
quantal acetylcholine release, 956
Ion transport, in vascular smooth muscle. *See* Vascular smooth muscle, ion transport

Iron
in free radical modulation, 149-150
in lipid peroxidation, 149
Ischemia, response of visceral afferent fibers, 125

J

J-receptors, respiratory system, 105

K

Kidney
blood flow regulation, 637-674
arterial blood pressure variability in conscious animals, 647-648
autoregulation, 667-673. *See also* Autoregulation
endothelial factors, 665
interactions between tubuloglomerular feedback mechanism of different nephrons, 657-659
interaction between synchronized nephrons, 657-658
mechanism of interaction, 658
nephron-nephron interaction in hypertensive rats, 659
populations of synchronized nephrons, 657
introduction, 637-638
myogenic response, 659-664
changes in hypertension, 664
chaos(?), 664
dynamic mathematical models of myogenic response and vasomotor oscillations, 663-664
mechanisms of vasomotor oscillations, 661-663
pharmacology of vasomotion, 663
studies on dynamics of, 660-661
vasomotion, 661
other intrarenal regulatory systems, 665
renin-angiotensin system, 665
spontaneous variability of renal blood flow, 665-667
summary and conclusions, 673-674
tubuloglomerular feedback system, 648-659. *See also* Kidney, tubuloglomerular feedback
ClC-K chloride channels, 819-820
magnesium handling, 305-317. *See also* Magnesium transport
pain, 115
sensory innervation, 115-116
sodium-glucose cotransporters, 1012
low-affinity sodium-glucose cotransporter (SGLT2), 999-1001
role in reabsorption of D-glucose, 1012-1015
concentrating capacity of SGLT1 and SGLT2 in rat kidney, 1013-1014
localization of rat SGLT1 and SGLT2 in nephron, 1012-1013
SGLT2 as low-affinity high-capacity system in renal proximal tubules, 1013
SGLT1 and SGLT2 from rat kidney, 1001-1002
SGLT1 expression in human kidney, 1015
tubuloglomerular feedback
chaotic tubular pressure fluctuations in hypertension, 655-657
chaos or noise, 655-656
possible causes of transition to chaos, 656
primary or secondary changes, 656-657
dynamic properties, 651-653
dynamics, 648-657
interactions between tubuloglomerular feedback mechanism of different nephrons, 657-659
macula densa response, 652
mathematical modeling, 653-655
mechanical factors affecting tubular signal propagation, 651-652
stop-flow pressure response, 652-653
tubular oscillations, 649-651
effect of diuretics, 650
mechanism of, 649-650
oscillations in early distal chloride concentrations, 650-651
oscillations in flow rate of tubular fluid, 650
spontaneous oscillations in tubular pressure and flow, 649
vasoconstriction, carotid chemoreceptor stimulation and, 562-563

L

Lactate dehydrogenase, ectothermic vertebrate heart, hypoxia and, 235
Lactic acid, skeletal muscle, fatigue and, 62-70, 82. *See also* Muscle fatigue
Lambert-Eaton syndrome, quantal acetylcholine release in, 954-955
α-Latroinsectotoxin, quantal acetylcholine release and, 935
α-Latrotoxin, quantal acetylcholine release and, 934-935
Ligases, in DNA replication, 271-272
inhibitors of DNA ligases, 295-297
Lipid(s), peroxidation, 147
iron in, 149
Liver
pain sensations, 109
sensory innervation, 109-110
Locus ceruleus, control of cardiovascular sympathetic premotor neurons, 343
Lorenz, attractors and differential equations, 11-12
Lungs
inflation, reflex effects on peripheral chemoreceptors, 550-552
rapidly adapting receptors, 552
slowly adapting receptors, 550-551
microvascular protein transport at low and high transvascular filtration rates, 199-200
sensory innervation, 104-105
sympathetic afferent fibers, 105
vagal afferent fibers, 104-105
sodium-glucose cotransport in, 1015
Lyapunov exponents, 20-22, 643
Lysosomes, calcium storage, 616

M

Magnesium
extracellular, modulation of calcium channels in muscle cells, 392
intracellular, inhibition of calcium channels in muscle cells, 405
intracellular free magnesium concentration, 305-307
control of, 306-307
determination of, 305-306
hormonal control of, 307
in mutant NMDA receptors, 747-748
Magnesium transport
distal tubule and collecting duct, hormonal influences, 316
factors influencing, 311-316
hormonal influences on magnesium reabsorption, 312-316
nonhormonal influences on magnesium reabsorption, 311-312
glomerular filtration and proximal tubule, 307-309
hormonal influences on magnesium reabsorption, 312-316
distal tubule and collecting duct, 316
loop of Henle, 313-316
proximal tubule, 313
urinary excretion, 312-313
intracellular free magnesium concentration, 305-307

introduction, 305
loop of Henle, 309–310
factors influencing, 312
hormonal influences, 313–316
cellular mechanisms in thick ascending limb, 314–316
segmental magnesium reabsorption, 309
transepithelial magnesium reabsorption, 309–310
nonhormonal influences on magnesium reabsorption, 311–312
loop of Henle, 312
proximal tubule, 311–312
physiological significance of plurihormonal control, 316–317
proximal tubule
factors influencing, 311–312
hormonal influences, 313
renal, 305–317
terminal nephron segments, 310–311
Magnetic resonance imaging (MRI), body fat distribution, 769–770
Magnetoencephalogram, chaos in, 33
mdr1, action as voume-activated chloride channel, 822
Medulla
caudal raphe nuclei, cardiovascular sympathetic premotor neurons, 335–336
caudal ventrolateral, control of cardiovascular sympathetic premotor neurons, 340–341
lateral tegmental field, control of cardiovascular sympathetic premotor neurons, 341
rostral ventrolateral, cardiovascular sympathetic premotor neurons, 328–334
rostral ventromedial, cardiovascular sympathetic premotor neurons, 335
Mesenteric capillaries, microvascular protein transport at low and high transvascular filtration rates, 198–199
Metabolic profile
abdominal obesity, 782–790
increased fatty acid flux and, 790–791
neuroendocrine factors, 791–795
body fat distribution and, 782–790. *See also* Body fat distribution, metabolic profile
weight loss and, 797–798
Metal ions, in free radical modulation, 149–150
Midbrain periaqueductal gray, control of cardiovascular sympathetic premotor neurons, 343–344
Miniature end-plate potential frequency (f_{MEPP})
evoked quantal acetylcholine release and, 919
potentiation
calcium and, 921
divalent metals and, 921–922
Mitochondria
calcium electrogenic uniport, 600–601
calcium storage, 616
ectothermic vertebrate heart, 225
ultrastructural/functional changes, muscle fatigue and, 79–80
MK-801, block of recombinant NMDA receptors, 748
Molecular biology, *N*-methyl-D-aspartic acid (NMDA) receptor, 724–729
Molecular physiology
intracellular calcium ctores. *See also* Calcium stores
intracellular calcium stores, 595–625
sodium-glucose transporters, 993–1021. *See also* Glucose transporters; Sodium-glucose transporters
voltage-gated chloride channels, 813–827. *See also* Chloride channels
Movement, motor function of cerebellorubrospinal system, 509–533
Mucosal receptors
esophagus, 106
small intestine, 112
stomach, 108
Muscarinic receptor, stimulation, calcium channel modulation in muscle cells, 421–423
Muscle cells
calcium channel regulation and modulation, 365–461. *See also* Calcium channel(s), regulation and modulation
ion transport in vascular smooth muscle cells. *See* Vascular smooth muscle
Muscle fatigue
blood glucose and muscle glycogen, 74–78, 82
blood glucose, 76–77
historical perspective, 74–75
muscle glycogen, 75–76
reduced carbohydrate oxidation and, 77–78
cell adenosine 5′-triphosphate as limiting factor, 72–74
cell phosphocreatine as limiting factor, 74
cellular mechanisms, 49–94
definition and current theories, 49–50
excitation-contraction coupling, 55–62, 81. *See also* Skeletal muscle, excitation-contraction coupling
sarcolemma action potential, 57–58
sarcolemma resting potential, 55–57
T tubular system, 58–60
T tubule-sarcoplasmic reticulum junction, 60–62
exercise intensity and environmental conditions, 51
high-energy phosphates and, 72–74, 82
hydrogen ion and, 65–70
intracellular pH and force, 66–68
pH, isometric relaxation rate, and sarcoplasmic reticulum ATPase, 69
pH and fiber maximal shortening velocity, 68–69
pH and glycolysis, 69–70
inorganic phosphate and, 70–72, 82
fiber maximal shortening velocity, 71–72
muscle force, 70–71
relaxation time, 71
lactic acid and intracellular pH, 62–70, 82
historical perspective, 62–63
hydrogen ion and muscle fatigue, 65–70
muscle lactate, 63–65
mechanical properties of muscle cell, 51–55
isometric contractile properties, 52–55
maximal shortening speed and peak power, 55
muscle fiber type composition, 50–51
muscle injury and, 78–79, 83
muscle lactate, 63–65
blood and muscle lactate and work capacity, 63–64
lactate efflux and effects of extracellular pH, 64–65
relation to cell pH, 65
summary and conclusions, 81–83
ultrastructural changes and, 79–81
mitochondria, 79–80
myofibrils, 80
T tubules and sarcoplasmic reticulum, 80–81
Mustard oil, response of visceral afferent fibers, 125
Myasthenia, congenital, quantal acetylcholine release in, 955
Myofibrils, ultrastructural/functional changes, muscle fatigue and, 80
Myogenic response. *See* Kidney, blood flow regulation
Myoglobin, ectothermic vertebrate heart, impact of oxygen-limiting conditions, 227–228

N

Neuroendocrine dysregulation hypothesis, abdominal obesity, 794
Neuromuscular junction
calcium channels in motor nerve terminals, 905–906. *See also* Calcium channel(s)

exocytotic apparatus, 927–930
ionic currents in motor nerve terminals, 902–906
frog, 902–903
mammals, 903
pharmacological dissection of presynaptic currents, 903–906
calcium currents, 905–906
potassium currents, 903–905
potassium currents, in motor nerve terminals, 903–905
quantal acetylcholine release. *See* Quantal acetylcholine release
synaptic efficacy, 953–954
Neurons
cardiovascular sympathetic premotor neurons, 328–338
central respiratory neurons, 553–556
cardiac vagal activity, 553–554
sympathetic activity, 554–556
sympathetic preganglionic neurons. *See* Central cardiovascular pathways
vagal pregnaglionic neurons, 324
Neuropeptide Y, receptor-mediated modulation of calcium channels in muscle cells, 431
Neurophysiology
chaos in complex neuronal networks, 2–5
chaotic behavior in cell assemblies and brain structures, 30–33
buccal ganglion of mollusks, 30
dimension evaluations of specific cortical structures in cats, 32–33
olfactory system of rabbit, 30–32
precentral and postcentral gyrus of squirrel monkey, 30
chaotic behavior in cell membranes, 28–30
giant axons of squid (*Doryteuthis bleekeri*), 29
giant internodal cell of freshwater algae (*Nitella flexilis*), 28–29
giant neurons in isolated esophageal ganglion of marine pulmonate mollusk (*Onchidium verruculatum*), 29
pond snail (*Lymnaea stagnalis*), 29
Hebbian cell assemblies, 38–40
pathological processes investigated by tools derived from theory of dynamic systems, 36–38
Neurosteroids, modulation of NMDA receptor activity, 734
Neurotransmitters. *See also specific neurotransmitters*
carotid body chemoreceptor response to, 858–861
in carotid body chemoreceptor (type I) cells
immunohistochemistry, 835–839
release, 846–851
carotid body metabolism, 843–846
cerebellar nuclear cells, 523
control of sympathetic preganglionic neurons, 327–328
red nucleus neurons, 521–522
Nitric oxide
carotid body chemoreceptor cell function and, 874
endothelium-derived, renal blood flow regulation, 665
***N*-Methyl-D-aspartic acid (NMDA) receptor,** 723–753
developmental regulation of function, 741–743
future directions, 753
introduction, 723–724
kinetics and synaptic transmission, 737–741
decay time course of excitatory postsynaptic current dictated by agonist affinity, 740
implications for synaptic transmission, 740–741
kinetic models underlying NMDA receptor excitatory postsynaptic current, 739–740
mediation of slow excitatory synaptic transmission, 737–738
molecular biology, 724–729
biochemical characterization of NMDA receptor subunits, 727–729
cloning of NMDA receptor subunits, 724
NMDA receptor gene families, 725–726
NMDAR2 splice variants, 727
structure and splice variants of NMDAR1, 726–727
native
allosteric interactions between glutamate and glycerine, 729–731
modulation by neurosteroids, 734–735
multiple allosteric actions of polyamines and histamine, 731–733
pH-sensitive modulating of receptor activity, 733
physiological properties, 729–735
redox sites, 733–734
recombinant, 743–750
agonists and competitive antagonists, 750–751
block by magnesium and calcium in mutant NMDA receptors, 748
block by MK-801, TCP, desipramine, and zinc, 748–749
influence of NR2 subunits on ion channel properties, 749–750
mutagenesis in TM2 reveals a site-controlling permeability and voltage-dependent block, 746–749
permeation of magnesium and calcium in mutant NMDA receptors, 747–748
pharmacological properties, 750–753
phosphorylation, 752–753
polyamines and, 751
protons and, 751–752
redox sites, 752
structure and function, 743–750
subunit composition, single-channel conductance and life time, 749
subunit-specific block by magnesium, 749
subunit-specific block by spider toxins, 750
subunit structure, 745–746
zinc and, 751
second messenger systems and cytoskeletal elements, 735–737
arachidonic acid and NMDA receptor function, 736–737
calcium-dependent inactivation and actin depolymerization, 736
modulation by protein kinases, 735–736
Nociception
biliary, 111
blood vessels, 103–104
cardiac pain, 102–103
morphology of nociceptive visceral endings, 123
visceral sensory receptors and visceral pain, 95–138
sensitization vs. silent nociceptors, 129
sensory vs. afferent fibers, 127–128
specificity vs. intensity theory of peripheral encoding of noxious events, 128–129
sympathetic vs. parasympathetic afferent fibers, 128
Nociceptor(s), 98
biliary, 111
cardiac, 102–103
silent, 125–126
visceral, 126–127, 129
Norepinephrine. *See also* Catecholamines
carotid body chemoreceptor response to, 860
neurotransmission at carotid body chemoreceptor cell-sensory nerve ending synapse and, 876
release and control, carotid body chemoreceptor output and, 848–851
Noxious stimulus, 96–97
peripheral encoding of noxious events, 99–100
pattern and intensity theories, 100
specificity theory, 100
visceral, 97–98
Nucleoside analogues
acyclic, inhibition of DNA polymerases, 286–287
base ring-modified, inhibition of DNA polymerases, 284–285
carbocyclic

inhibition of DNA polymerases, 286–287
inhibition of HIV reverse transcriptase, 291
sugar moiety-modified, inhibition of DNA polymerases, 285–287
Nucleoside phosphonates, acyclic, inhibition of HIV reverse transcriptase, 291–292
Nucleus tractus solitarii, central processing of cardiovascular afferent inputs, 338–340
efferent outputs, 340
modulation of signal transmission, 339–340
neurotransmitters of primary afferent fibers, 338–339
sites of termination of primary afferent fibers, 338

O

Obesity
abdominal
genetic considerations, 795–797
increased fatty acid flux in, 790–791
metabolic profile, 782–790. *See also* Body fat distribution, metabolic profile and
increased fatty acid flux and, 790–791
neuroendocrine factors, 791–795
sex hormones and sexual dimorphism and, 791–794
stress and hypothalamic arousal syndrome and, 794–795
weight loss and, 797–798
cancer and, 764
cardiovascular disease and, 764
disease risk, 763–764
body fat distribution and, 764–767
hyperinsulinemia and, 764
lower body (android), historical aspects, 762
non-insulin-dependent diabetes mellitus and, 763–764
psychogenic theory, 781
regional adiposity and morbidity, 761–800. *See also* Body fat distribution
epidemiology, 763–764
upper body (gynoid), historical aspects, 762
Olfactory system, chaotic behavior (rabbit), 30–32
Opioid peptides
carotid body chemoreceptor response to, 861
carotid body metabolism, 846
neurotransmission at carotid body chemoreceptor cell-sensory nerve ending synapse and, 877
Orosomucoid, vascular large-solute permeability and, 207–208
Osmolarity, carotid body chemoreceptor response to, 856–857
Oxygen
arterial content, peripheral chemoreceptor function and, 546
partial pressure, arterial, peripheral chemoreceptor function and, 545
Oxygen free radicals. *See* Free radicals

P

Pain
cardiac, 101
peripheral mechanisms, 102–103
colorectal, 113, 114–115
esophageal, 106, 107
gastric, 108–109
gynecological, 119–120
hepatobiliary, 109, 111
obstetric, 120
pancreatic, 109
renal and ureteric, 115
small intestine, 111, 113
testicular, 121
urinary tract, lower, 117, 119
visceral. *See* Visceral pain; Visceral sensory receptors
Pancreas
pain, 109
sensory innervation, 110–111
Parabrachial complex, control of cardiovascular sympathetic premotor neurons, 342–343
Parasympathetic afferent fibers, 99
colorectal innervation, 114
Parathyroid hormone, receptor-mediated modulation of calcium channels in muscle cells, 430–431
Paraventricular nucleus, cardiovascular sympathetic premotor neurons, 337
Pardaxin, quantal acetylcholine release and, 935–936
Pattern theory, peripheral encoding of noxious events, 100
Peripheral chemoreceptors, 543–584
abdominal chemoreceptor stimulation, 570–571
adrenal hormones and, 571–572
aortic chemoreceptor stimulation, 569–570
in breath-hold diving, 580
cardiovascular response to carotid chemoreceptor stimulation, 559–566
cardiac output, 560
cerebral circulation, 563–565
coronary circulation, 560–561
heart rate, 559–560
inotropic effects, 560
kidney, 562–563
limb circulation, 561
pulmonary circulation, 565–566
skeletal muscle, 561
skin, 562
splanchnic circulation, 562
systemic vascular capacity, 566
central neural pathways, 575–577
central respiratory neurons, 553–556
cardiac vagal activity, 553–554
sympathetic activity, 554–556
in exercise, 580
experimental stimulation, 548–549
functional role, 577–584
in hemorrhage, 581–584
hypocapnia and, 552–553
interactions between responses evoked by chemoreceptors and other receptors, 572–575
baroreceptors, 574–575
cardiac receptors, 573
cardiopulmonary receptors, 572–573
central chemoreceptors, 575
facial and upper airway receptors, 573–574
pulmonary receptors, 573
introduction, 544
location and structure, 544–545
natural stimulation, 545–548
arterial oxygen content, 546
arterial pressure, 546
circulating influences, 548
dynamic influences, 546–547
effects of efferent nerves, 547–548
potassium, 546

steady-state changes in arterial partial pressure of oxygen, arterial partial pressure of carbon dioxide, and pH, 545
primary and secondary responses elicited by stimulation, 549–550
reflex effects of lung inflation, 550–552
rapidly adapting receptors, 552
slowly adapting receptors, 550–551
renin-angiotensin system and, 572
respiratory-dependent effects in different species, 556–559
cat, 557–558
dog, 556–557
primate, 558–559
rabbit, 558
rat, 558
seal, 558
responses evoked by stimulation in fetus and neonate, 571
role in brain stem defense areas, 566–569
in sleep, 580–581
in systemic hypoxia, 577–580
tonic influence, 577
vasopressin and, 572
Peritoneum, microvascular protein transport at low and high transvascular filtration rates, 198–199
Pertussis toxin, receptor-mediated modulation of calcium channels in muscle cells, 416
P-glycoprotein, action as voume-activated chloride channel, 822
pH
intracellular
ectothermic vertebrate heart, acidosis and, 241
ectothermic vertebrate heart contractility under hypoxia and, 237
low, carotid body chemoreceptor response to, 855–856
modulation of NMDA receptor activity, 733
muscle fatigue and, 65–70
glycolysis and, 69–70
intracellular pH and force, 66–68
isometric relaxation rate and sarcoplasmic reticulum ATPase, 69
pH and fiber maximal shortening velocity, 68–69
peripheral chemoreceptor function and, 545
sodium-hydrogen exchange in vascular smooth muscle and, 697
Phenothiazines, calcium channel modulation in muscle cells, 443
Phenylalkylamines, modulation of calcium channels in muscle cells, 433–441. *See also* Calcium channel blockers
Phosphatases, calcium channel modulation in muscle cells, 449–450
Phosphate(s)
high-energy, muscle fatigue and, 72–74, 82
inorganic
ectothermic vertebrate heart, hypoxia and, 236–237
muscle fatigue and, 70–72, 82
skeletal muscle concentration, 70
Phosphocreatine, intracellular, muscle fatigue and, 74
Phosphofructokinase, ectothermic vertebrate heart, hypoxia and, 233–235
Phosphoinositide signaling system, calcium channel regulation in muscle cells, 413–414
Phospholamban, effects on calcium-magnesium-adenosinetriphosphatase, sarcoplasmic reticulum, 695
Phospholemman, volume-activated chloride channel or regulator, 821–822
Phospholipase(s), antioxidant defense, 146
Phospholipase C, second messengers, carotid body chemoreceptor cell function and, 874
Phosphorylation, NMDA receptors, 752
Physical activity, body fat distribution and, 779
Physiology
basic principles of theory of dynamic systems, 8–26. *See also* Dynamic systems
nonlinear dynamics. *See* Chaos
nonlinear systems analysis in, 6–8
Pointwise scaling dimension. *See* Dynamic systems, pointwise dimension
Polyamines
allosteric regulation of NMDA receptors, 731–733
NMDA receptors and, 751
Polymerases, in DNA replication, 267–268
inhibitors of cellular and virus-encoded DNA polymerases, 283–288
Postcentral gyrus, chaotic behavior (squirrel monkey), 30
Postpoliomyelitis syndrome, quantal acetylcholine release in, 955
Potassium
effects on sodium-potassium pump, 686–687
peripheral chemoreceptor function and, 546
skeletal muscle fatigue, 56–57
Potassium channel(s), presynaptic, evoked quantal acetylcholine release, 907–908
adenosine 5′-triphosphate-dependent potassium current, 908
calcium-activated potassium current, 907–908
fast potassium current, 907
plateau current and release, 908
Potassium current(s)
carotid body chemoreceptor cells from adult animals, 863–864
in motor nerve terminals, 903–905
quantal acetylcholine release. *See* Potassium channel(s), presynaptic
Potassium-hydrogen-adenosinetriphosphatase, vascular smooth muscle, 689–690
Potentiation, quantal acetylcholine release, 920–922, 958
Precentral gyrus, chaotic behavior (squirrel monkey), 30
Primases, in DNA replication, 268
Prokaryotes, model of DNA replication, 262
Proliferating cell nuclear antigen, in DNA replication, 269
Pronase, calcium channel modulation in muscle cells, 450
Propionate, quantal acetylcholine release, estimation of number of quanta released, 941–942
Prostaglandin(s)
carotid body chemoreceptor cell function and, 874
PGE_2, neurotransmission at carotid body chemoreceptor cell-sensory nerve ending synapse and, 876–877
Proteases, calcium channel modulation in muscle cells, 450–451
Protein(s)
contractile, ectothermic vertebrate heart, hypoxia and, 236–237
in DNA replication, 261–262. *See also* DNA replication, enzymes and proteins at replication fork
initiator proteins, 265–266
free radical-induced oxidative damage, 146–147
plasma, passive transport across large pores in continuous vascular endothelia, 165–167. *See also* Transvascular transport
quantal acetylcholine release, 927–930, 959
vascular large-solute permeability and, 206–207
Protein kinase(s), modulation of NMDA receptor activity, 735–736
Protein kinase A, effects on sodium-potassium pump, 688
Protein kinase C
calcium channel regulation in muscle cells, 413–414
effects on sodium-potassium pump, 688
sodium-hydrogen exchange in vascular smooth muscle and, 697–698
Protons
external, modulation of calcium channels in muscle cells, 402
intracellular, inhibition of calcium channels in muscle cells, 406
NMDA receptors and, 751–752
Psychogenic theory, obesity, 781
Pulmonary circulation, carotid chemoreceptor stimulation and, 565–566
Pulmonary receptors, interactions with peripheral chemoreceptors, 573

Purine biosynthesis, de novo, 275–276
Purinergic receptors, stimulation, calcium channel modulation in muscle cells, 425–427
Purkinje cells, cerebellar. *See* Cerebellorubrospinal system
Pyrimidine biosynthesis, de novo, 275–276
Pyruvate kinase, ectothermic vertebrate heart, hypoxia and, 235

Q

Quantal acetylcholine release, 899–963
active zone, calcium channel localization, and release, 957
botulinum neurotoxin and, 930–933
binding, 931
evoked release, 932–933
internalization, 931
nonquantal release, 932
spontaneous quantal release, 931–932
calcium and, 906–914
calcium concentration and time course of evoked release, 909–911
direct measurement, 909
estimates by deconvolution, 910–911
measurement from latencies, 909–910
temperature and time course of release, 911
calcium cooperativity in quantal release, 908–909
consideration of resting intracellular calcium, 908–909
cooperativity in other cells, 909
entering calcium and release, 906
localization of calcium channels, 906–907. *See also* Calcium channel(s), in motor nerve terminals
presynaptic potassium channels, 907–908
adenosine 5′-triphosphate-dependent potassium current, 908
calcium-activated potassium current, 907–908
fast potassium current, 907
plateau currents and release, 908
release by nerve terminal electrical depolarization, 911–914
abrupt elevation in intracellular calcium, 913–914
calcium-voltage hypothesis, 912–913
temperature and evoked release, 909
cotransmitters, 949–950
adenosine 5′-triphosphate, 949
calcitonin gene-related peptide, 949–950
substance P, 950
vasoactive intestinal peptide, 950
dense vesicles, 949
depression, 939–940, 962
diseases altering release, 954–955
amyotrophic lateral sclerosis, 955
congenital myasthenia, 955
diabetes mellitus, 955
Lambert-Eaton syndrome, 954–955
naturally occurring toxins, 955
postpoliomyelitis syndrome, 955
Drosophila, 948
early release period, 957–958
factors altering, 962–963
feedback regulation, 962
independence of, 914, 958
introduction, 900–901
aims of review, 900–901
why quanta, 901
ionic currents in motor nerve terminals, 902–906, 956
frog, 902–903
mammals, 903
pharmacological dissection of presynaptic currents, 903–906
calcium currents, 905–906
potassium currents, 903–905
models of evoked quantal release, 926–927
oscillation of, 914–915
other cell types, 948
plasticity in crustaceans, 925–926
facilitation and augmentation, 925
long-term adaptation, 926
long-term facilitation, 925
serotonin-induced enhancement, 926
potentiation, 920–922
calcium and f_{MEPP} potentiation, 921
divalent metals, f_{MEPP}, and elevated potassium, 922
other divalent metals and f_{MEPP} potentiation, 921–922
role of sodium, 920–921
trivalent metals, 922
preferential release of newly synthesized acetylcholine, 961–962
proteins and, 927–930, 959
enzymes, energetics, and release, 930
exocytotic apparatus, 927–930, 959
localization in motor nerve terminal, 929–930
membrane proteins, 928
other proteins, 928–929
role in motor nerve terminal, 929–930
20S particle, 927
at synapse, 929
vesicle, 927–928
quantal loading and turnover, 936–948, 960–961
acetylcholine content and turnover, 945–947
acetylcholine leak, 946–947
blowfly, 947
frog, 947
mammal, 946–947
depression, 939–940
Drosophila, 948
number of quanta released without replenishment, 940–943
estimate in low calcium, 941
estimate with hemicholinium-3, 942
estimate with propionate, 941–942
estimate with vesamicol, 942–943
regulation of acetylcholine synthesis, 945
Torpedo electric organ, 936–937
two-stage acetylcholine loading, 948
vesicle cycling, 943–945
estimates with false transmitter, 944–945
estimates with fluorescent stain, 943–944
vesicles and quantal release, 937–939
short-term chemical regulation, 950–953
adenosine, 952
cholinergic effects, 950–952
curare and tetanic fade, 951–952
frog, 950
mammal, 950–951
Torpedo, 950
substances from end plate, 952–953
statistics, 914–916
independence and release statistics, 915, 958
independence of quantal release, 914
interactions at a distance along terminals, 915–916
oscillation of quantal release, 914–915
stimulus-induced increases in evoked and spontaneous release, 916–926, 958–959
augmentation, 920, 958
calcium removal processes, 925
common features of facilitation and delayed release, 919–920

delayed release, 919
drugs and hormones, 923
facilitation, 917–918, 919–920, 958
interactions of treatments, 924
miniature end-plate potential frequency (f_{MEPP}) and evoked release, 919
model for regulation by calcium, 924–925
plasticity in crustaceans, 925–926
potentiation, 920–922
tonicity of solution, 922–923
summary and conclusions, 955–963
tetanus toxin and, 933
toxins blocking, 930–934, 959–960
botulinum neurotoxins, 930–933
targets of toxins, 933–934
tetanus toxin, 933
toxins promoting release, 934–936, 960
glycerotoxin, 935
α-latroinsectotoxin, 935
α-latrotoxin, 934–935
pardaxin, 935–936
variations in synaptic efficacy, 953–954
age and development, 954
exercise, 954
type of muscle fiber, 953–954
vesicles and quantal release, 937–939
endocytosis, 938–939
maximal quantal output, 937–938
morphology of quantal release, 938
number of quanta in end-plate potential, 937

R

Reactive oxygen species. *See* Free radicals
Rectum
pain, 114–115
sensations from, 113
sensory innervation, 113–114
parasympathetic afferent fibers, 114
sympathetic afferent fibers, 114
Red nucleus. *See* Cerebellorubrospinal system
Renin-angiotensin system
peripheral chemoreceptor stimulation and, 572
renal blood flow regulation, 665, 672
Replication factor C, in DNA replication, 269–270
Reproductive organs
female
obstetric and gynecological pain, 119–120
sensory innervation of internal genitalia, 120
sensory receptors in uterus, 120–121
male
sensations from internal genitalia, 121
sensory innervation of internal genitalia, 122
sensory receptors in testes, 122
sensory innervation, 119–122
female, 119–121
male, 121–122
Reptiles, heart metabolism and contractility. *See* Ectothermic vertebrate heart
Respiratory system
pain mechanisms, 105–106
sensations from, 104
sensory innervation, 104–105
sympathetic afferent fibers, 105
vagal afferent fibers, 104–105
J-receptors, 105
rapidly adapting stretch receptors, 105
slowly adapting stretch receptors, 104–105
Reticular formation, chaotic behavior, dimensional evaluations in cats, 32–33
Rössler, attractors and differential equations, 11–12
Ryanodine, rapidly exchanging calcium pools, 618–619
Ryanodine receptor
calcium release, 603–607
cellular expression, 606–607
function and regulation, 604–606
molecular structure, 603–604

S

***Saccharomyces cerevisiae* origin recognition complex,** DNA replication, 266
Sarcolemma
ectothermic vertebrate heart, 225–226
skeletal muscle
action potential, 57–58
resting potential, 55–57
Sarcoplasmic reticulum
adenosinetriphosphatase
calcium-magnesium, 693–696
pH and, 69–70
calcium stores, 610–611
ectothermic vertebrate heart, 224–225
ultrastructural/functional changes, muscle fatigue and, 80–81
Schizophrenia, investigation by tools derived from theory of dynamic systems, 38
Secondary ion mass spectrometry microscopy, organelle calcium, 622
Secretion granules, calcium storage, 615
Selenium, in free radical modulation, 150–151
Sensory innervation
biliary system, 110
cardiovascular system, 100–104
colon and rectum, 113–114
esophagus, 106–107
gastrointestinal tract, 106–115
heart, 101–102
intracranial structures, 122–123
kidney, 115–116
liver, 109–110
pancreas, 110–111
reproductive organs, 119–122
female, 119–121
male, 121–122
respiratory system, 104–106
small intestine, 111–113
spleen, 122
stomach, 107–109
ureter, 116
urinary tract, 115–119
viscera. *See also* Visceral sensory receptors
afferent innervation vs., 98–99
Septal nuclei, control of cardiovascular sympathetic premotor neurons, 346
Serotonin. *See* 5-Hydroxytryptamine
Sex hormones, body fat distribution and, 780–781, 791–794
Sexual dimorphism, body fat distribution and, 780–781, 791–794
SGLT. *See* Sodium-glucose cotransporters

Simian virus 40 large T antigen, DNA replication, 265
Skeletal muscle
adenosine 5′-triphosphate content, 72
exercise-induced alterations, 72
calcium channel regulation and modulation, 365–461. *See also* Calcium channel(s), regulation and modulation
ClC-1 voltage-dependent chloride channel, 816–818
excitation-contraction coupling, 55–62
sarcolemma action potential, 57–58
sarcolemma resting potential, 55–57
T tubular system, 58–60
T tubule-sarcoplasmic reticulum junction, 60–62
fatigue. *See* Muscle fatigue
fiber maximal shortening velocity
inorganic phosphate and, 71–72
pH and, 68–69
fiber type, synaptic efficacy and, 953–954
fiber type composition, fatigue and, 50–51, 81
force generation
inorganic phosphate and, 70–71
intracellular pH and, 66–68
injury, muscle fatigue and, 78–79, 83
inorganic phosphate concentration, 70
mechanical properties of muscle cell, 51–55
isometric contractile properties, 52–55
maximal shortening speed and peak power, 55
microvascular protein transport at low and high transvascular filtration rates, 198
phosphocreatine content, 72
exercise-induced alterations, 72
relaxation time
inorganic phosphate and, 71
pH and, 68–69
sarcolemma resting potential, 55–57
potassium and cell depolarization, 56–57
sodium-potassium pump, 57
T tubules
activity-induced change in function, 59–60
excitation-contraction coupling, 58–60
physiological role, 59
ultrastructural/functional changes, muscle fatigue and, 80–81
T tubule-sarcoplasmic reticulum junction, 60–62
activity-induced changes in calcium release, 61–62
physiological characteristics, 60–61
ultrastructural changes, muscle fatigue and, 79–81
vasoconstriction, carotid chemoreceptor stimulation and, 561
Skin, vasoconstriction, carotid chemoreceptor stimulation and, 562
Skin-fold thickness, 767
Sleep, peripheral chemoreceptors in, 580–581
Smoking, body fat distribution and, 779
Sodium
effects on sodium-potassium pump, 686–687
extracellular, modulation of calcium channels in muscle cells, 392–394
Sodium-calcium exchange, vascular smooth muscle, 702–705
Sodium channel blockers, calcium channel modulation in muscle cells, 443–444
Sodium current(s), carotid body chemoreceptor cells from adult animals, 863
Sodium-glucose cotransporters, 993–1021
biochemical characterization, 996–997
cell physiology, 996
electrogenic properties, 1007–1012
analysis of steady-state currents of SGLT1, 1008–1010
ordered kinetic model of SGLT1, 1008
relaxation studies of SGLT1, 1010–1012
stoichiometry, 1007–1008
expression cloning of rabbit intestinal Na^+-glucose cotransporter (SGLT1), 997–998
expression in epithelial tissues, 1012–1015
glucose transport in choroid plexus, 1015
SGLT1 and SGLT2 in rat intestine and kidney, 1012
SGLT1 and SGLT2 in renal reabsorption of D-glucose, 1012–1015
concentrating capacity of SGLT1 and SGLT2 in rat kidney, 1013–1014
localization of rat SGLT1 and SGLT2 in nephron, 1012–1013
SGLT2 as low-affinity high-capacity system in renal proximal tubules, 1013
SGLT1 in human kidney, 1015
SGLT1 in human intestine, 1012
sodium-glucose cotransport in lung, 1015
intestinal sodium-glucose cotransport in fluid absorption, 995–996
introduction, 993–994
kidney low-affinity Na^+-glucose cotransporter (SGLT2), 999–1001
primary structures of other ion-coupled solute transporters, 998
regulation of expression, 1015–1020
alteration of sodium-glucose transport in diabetes mellitus, 1017–1018
dietary dependence of SGLT1 expression, 1015–1016
expression of sodium-glucose transporters in cultured cells, 1018–1020
SGLT1 expression in sheep intestine, 1016–1017
SGLT1 and SGLT2 from rat kidney, 1001–1002
SGLT1 and SGLT2 genes, 1020–1021
chromosome localizations and genetic structures, 1020
inherited defects in sodium-glucose cotransport, 1020–1021
SGLT1 expression in epithelial tissues: functional implications, 1012–1015
SGLT family of sodium-coupled solute transporters, 1003
SGLT1 from human intestine (ileum), 999
SGLT1 function: monomer or oligomer, 1002–1003
structure-function relationships, 1003–1012
electrogenic properties, 1007–1012
sodium and glucose binding site locations, 1003–1006
topology in membrane, 1006–1007
summary and future perspectives, 1021
Sodium-hydrogen exchange, vascular smooth muscle, 696–702
characteristics, 696–697
measurement, 696
physiological significance, 700–702
regulation, 697–700
adrenergic agonists, 699
angiotensin II, 698
atrial natriuretic factor (peptide), 699
calcium and protein kinase C, 697–698
growth factors, 699–700
heparin and glucocorticoids, 700
pH, 697
thrombin, 698–699
vasoactive peptides, 699
Sodium-potassium-adenosinetriphosphatase, vascular smooth muscle, 685–689
characteristics, 686
measurement, 686
physiological significance, 688–689
regulation, 686–688
effects of calcium, cadmium, and vanadate, 687–688
effects of sodium and potassium, 686–687
protein kinase C and protein kinase A in, 688
Sodium-potassium-chloride cotransport, vascular smooth muscle, 705–708

Sodium-potassium pump
sarcolemma, skeletal muscle fatigue, 57
vascular smooth muscle. *See* Sodium-potassium-adenosinetriphosphatase
Somatostatin, receptor-mediated modulation of calcium channels in muscle cells, 431
20S particle, 927
Specificity theory, peripheral encoding of noxious events, 100
Splanchnic circulation, carotid chemoreceptor stimulation and, 562
Spleen, sensory innervation, 122
Starling fluid balance, heteroporosity effects on
coupling of net steady-state fluid flow to capillary hydrostatic pressure, 186–187
coupling of net steady-state fluid flow to plasma colloid osmotic pressure, 187–188
Stomach
pain, 108–109
sensations from, 107–108
sensory innervation, 108
Stress, body fat distribution and, 781–782, 794–795
Subcutaneous tissue, microvascular protein transport at low and high transvascular filtration rates, 198
Substance P
carotid body chemoreceptor response to, 861
carotid body metabolism, 846
corelease with acetylcholine, 950
receptor-mediated modulation of calcium channels in muscle cells, 431
Superoxide dismutase, antioxidant defense, 145
Superoxide radical, 140
Sustentacular cells, carotid body, 832–833
Sympathetic afferent fibers, 99
cardiac innervation, 102
colorectal innervation, 114
esophageal innervation, 106–107
gastric innervation, 108
respiratory system innervation, 105
small intestine innervation, 112
Synaptic transmission
neurotransmission at carotid body chemoreceptor cell-sensory nerve ending synapse, 874–877
NMDA receptor excitatory postsynaptic current
decay time course, agonist affinity and, 740
kinetic models underlying, 739–740
slow excitatory, NMDA receptor mediation of, 737–738
sympathetic preganglionic neurons, 326–327
synaptic efficacy at neuromuscular junction, 953–954
age and development and, 954
exercise and, 954
type of muscle fiber and, 953–954
Systemic vascular capacity, carotid chemoreceptor stimulation and, 566

T

TCP, block of recombinant NMDA receptors, 748
Temperature
carotid body chemoreceptor response to, 856–857
ectothermic vertebrate heart metabolism and contractility, 245–249
acute temperature transitions above freezing, 245–246
chronic low-temperature exposure above freezing, 246–249
quantal acetylcholine release and, 909
time course of release and, 911
reduction, effect on transvascular large-solute transport, 166
Tension receptors
esophagus, 106
"in series," stomach, 108
small intestine, 112
Testis
pain, 121
sensory receptors in, 122
Tetanus toxin, quantal acetylcholine release and, 933
Tetrandrine, calcium channel modulation in muscle cells, 446
Thapsigargin, rapidly exchanging calcium pools, 617
Third ventricle, anteroventral region, control of cardiovascular sympathetic premotor neurons, 345
Thrombin
receptor-mediated modulation of calcium channels in muscle cells, 430
sodium-hydrogen exchange in vascular smooth muscle and, 698–699
Tinnitus, investigation by tools derived from theory of dynamic systems, 38
Topoisomerases, in DNA replication, 270–271
inhibitors of DNA topoisomerases, 293–295
***Torpedo* spp.**
ClC-0 voltage-dependent chloride channel, 815–816
electric organ, quantal acetylcholine release, 936–937
Toxins
calcium channel modulation in muscle cells, 444
naturally occurring, 955
quantal acetylcholine release and
toxins blocking release, 930–934, 959–960
toxins promoting release, 934–936, 960
Transcytosis, 163, 164–165
Transferrin, in free radical modulation, 150
Transvascular transport, 163–219
assessment techniques, 192–197
critique of lymphatic protein flux analyses, 194–195
critique of tissue uptake studies in animals, 195–197
general aspects, 192
integral mass-balance technique for assessing reflection coefficient, 193–194
reversed osmotic transient method, 193
single capillary analyses, 192–193
single injection residue function technique, 193
computer-simulated behavior of two-pore (heteroporous) system, 180–188
coupling of solute flux to transcapillary volume flow in heteroporous membranes: effects of increases in capillary hydrostatic pressure vs. hemodilution, 185–186
differential steady-state albumin fluxes in small and large pores: relationships between diffusive and convective fluxes, 183–185
heteroporosity effects on Starling fluid balance
coupling of net steady-state fluid flow to capillary hydrostatic pressure, 186–187
coupling of net steady-state fluid flow to plasma colloid osmotic pressure, 187–188
partitioning of fluid flows among two major fluid conductive pathways
non-steady-state conditions, 180–181
steady-state conditions, 181–182
steady-state large-solute clearances and sieving coefficients in two-pore membrane, 182–183
continuous capillaries
protein transport in various vascular beds at low and high transvascular filtration rates, 198–200
structure-function correlations, 202–204
fenestrated capillaries

protein transport in various vascular beds at low and high transvascular filtration rates, 200–202
structure-function correlations, 204–205
heteroporous models, 174–177
homoporous models, 167–169
introduction, 163–164
large-solute
assessment, 167–180
homoporous approaches for assessing permeability-surface area product and reflection coefficient in lymphatic protein flux analyses, 169–173
homoporous models, 167–169
effects of chemical fixation of endothelium, 167
evaluation of transcapillary large-solute transfer at low lymph flow states: pore modeling, 188–192
heteroporous models, 174–177
fractional contribution of diffusion and convection to total large-solute flux, 176–177
partitioning of fluid fluxes among different fluid pathways in heteroporous membrane, 174–175
recalculation of homoporous reflection coefficient and permeability-surface area product from heteroporous models, 176
restricted transport through aqueous channels, 176
solute fluxes through heteroporous membrane
linear approximations, 175
nonlinear transport equations, 176
homoporous approaches for assessing permeability-surface area product and reflection coefficient in lymphatic protein flux analyses, 169–173
homoporous models, 167–169
linear transport formalism, 167
nonlinear transport formalism, 167–168
permeability-surface area product, 168–169
lymphatic protein flux analyses, 169–173
modulation of vascular permeability, 205–209
albumin effect, 206–207
autacoids and, 205–206
high vascular pressures and, 208–209
neutral dextran and, 208
orosomucoid effect, 207–208
protein effect, 206–207
temperature reductions and, 166
transcytosis hypothesis, 164–165
morphological data challenging, 167
vascular wall charge and, 177–180
application of double-layer model to experimental data, 179–180
Donnan distribution and Donnan potential, 178
general phenomena associated with capillary wall charge, 178
partitioning of molecules in charged membranes
double-layer model, 178–179
modified Nernst-Planck equation, 179
lymphatic protein flux analyses
assessment techniques, 192–194
critique, 194–195
general aspects, 192
homoporous approaches for assessing permeability-surface area product and reflection coefficient, 169–173
linear flux equation
cross-point method, 170–171
for semipermeable membrane, 169–170
slope method, 170
nonlinear flux equation
limiting slope technique, 171–173
wash-down technique, 171
integral mass-balance technique for assessing reflection coefficient, 193–194
reversed osmotic transient method, 193
single capillary analyses, 192–193
single injection residue function technique, 193
modulation of vascular large-solute permeability, 205–209
albumin effect, 206–207
autacoid effects, 205–206
high vascular pressure and, 208–209
neutral dextran and, 208
orosomucoid effect, 207–208
protein effect, 206–207
passive transport of plasma proteins across large pores in continuous endothelia, 165–167
chemical fixation of endothelium and large-solute transport, 167
general considerations, 165
morphological data challenging transcytosis hypothesis, 167
temperature reductions and large-solute transport, 166
volume recirculation concept, 165–166
permeability-surface area product
homoporous models, 168–169
recalculation from heteroporous models, 176
lymphatic protein flux analyses, 169–173
protein transport in various vascular beds at low and high transvascular filtration rates, 197–202
continuous capillaries, 198–200
fenestrated capillaries, 200–202
gastrointestinal capillaries, 200–201
general considerations, 197–198
glomerular capillaries, 201–202
lung capillaries, 199–200
peritoneal and mesenteric capillaries, 198–199
subcutaneous tissue and muscle capillaries, 198
structure-function correlations
continuous capillaries, 202–204
fiber matrix concept, 204
slit concept, 202–204
fenestrated capillaries, 204–205
transcytosis, 163, 164–165
morphological data challenging transcytosis hypothesis, 167
two-pore (heteroporous) system, 180–192
computer-simulated results, 180–188
evaluation of transcapillary large-solute transfer at low lymph flow states: pore modeling, 188–192
protein transport in various vascular beds at low and high transvascular filtration rates, 197–202
vesicle controversy, 164–167
passive transport of plasma proteins across large pores in continuous endothelia, 165–167
transcytosis hypothesis, 164–165
morphological data challenging, 167
Trypsin, calcium channel modulation in muscle cells, 450
T tubules. *See* Skeletal muscle, T tubules
Tubocurarine, short-term regulation of quantal acetylcholine release, 951–952
Tubuloglomerular feedback. *See* Kidney, tubuloglomerular feedback
Turpentine oil, response of visceral afferent fibers, 125

U

Ultrasonography, body fat distribution, 770
Ureter
pain, 115

sensory innervation, 116
Urethra
sensations from, 116–117
sensory innervation, 119
Uric acid, antioxidant properties, 144–145
Urinary tract
lower
pain, 117
sensations from, 116–117
sensory innervation, 117–119
sensory innervation, 115–119
bladder and urethra, 116–119
kidney and ureter, 115–116
Urine, magnesium excretion, 312–313
Uterus
pain, 120
sensory receptors, 120–121

V

Vagal afferent fibers
cardiac innervation, 101–102
esophageal innervation, 106
gastric innervation, 108
respiratory system innervation, 104–105
small intestine innervation, 112
Vanadate, effects on sodium-potassium pump, 687–688
Vascular headache, 103
Vascular pressure, elevated, vascular large-solute permeability and, 208–209
Vascular smooth muscle
ion carriers, 696–710
chloride-bicarbonate exchange, 708–710
characteristics, 709–710
measurement, 709
physiological significance, 710
regulation, 710
sodium-calcium exchange, 702–705
characteristics, 702–703
measurement, 702
physiological significance, 704–705
regulation, 703–704
sodium-hydrogen exchange, 696–702
characteristics, 696–697
measurement, 696
physiological significance, 700–702
regulation, 697–700
sodium-potassium-chloride cotransport, 705–708
characteristics, 706
measurement, 705–706
physiological significance, 707–708
regulation, 706–707
ion pumps, 685–696
calcium-magnesium-adenosinetriphosphatase, 690–696. *See also* Calcium-magnesium-adenosinetriphosphatase
plasma membrane, 690–693
sarcoplasmic reticulum, 693–696
potassium-hydrogen-adenosinetriphosphatase, 689–690
sodium-potassium-adenosinetriphosphatase, 685–689
characteristics, 686
measurement, 686
physiological significance, 688–689
regulation, 686–688
ion transport, 683–712
conclusions, 711–712
introduction, 683–685
ion carriers, 696–710
ion pumps, 685–696
Vascular system. *See* Blood vessels; Cardiovascular system; Cerebrovascular system
Vasoactive intestinal peptide, corelease with acetylcholine, 950
Vasoactive peptides, sodium-hydrogen exchange in vascular smooth muscle and, 699
Vasomotion, 661
dynamic mathematical models of vasomotor oscillations, 663–664
mechanisms of vasomotor oscillations, 661–663
pharmacology, 663
Vasopressin
peripheral chemoreceptor stimulation and, 572
receptor-mediated modulation of calcium channels in muscle cells, 431
Vein(s), pain sensitivity, 103–104
Vesamicol, quantal acetylcholine release, estimation of number of quanta released, 942–943
Viruses, model of DNA replication, 262–263
Visceral innervation
afferent vs. sensory, 98–99
sensory. *See* Visceral sensory receptors
sympathetic and parasympathetic afferents, 99
Visceral pain
afferent vs. sensory innervation of viscera, 98–99
altered visceral sensations after repetitive stimulation or inflammation, 124
cardiac, 101
peripheral mechanisms, 102–103
colorectal, 113, 114–115
esophageal, 106, 107
gastric, 108–109
hepatobiliary, 109, 111
obstetric and gynecological, 119–120
pancreatic, 109
peripheral encoding of noxious events, 99–100
pattern and intensity theories, 100
specificity theory, 100
specificity vs. intensity theory, 128–129
renal and ureteric, 115
respiratory system, 105–106
sensitization vs. silent nociceptors, 129
sensory innervation of viscera and, 95–138
sensory vs. afferent fibers in, 127–128
small intestine, 111, 113
specificity vs. intensity theory of peripheral encoding of noxious events, 128–129
sympathetic and parasympathetic afferents, 99
sympathetic vs. parasympathetic afferent fibers in, 128
testicular, 121
urinary tract
lower, 117, 119
renal and ureteric, 115
Visceral sensory receptors, 95–138
basic concepts, 96–99
afferent vs. sensory innervation of viscera, 98
nociceptor, 98
noxious stimulus, 96–97
visceral, 97–98
cardiovascular system, 100–104
gastrointestinal system, 106–115
colon and rectum, 113–115
esophagus, 106–107

liver, biliary system, and pancreas, 109–111
small intestine, 111–113
stomach, 107–109
introduction, 95–96
morphology of nociceptive visceral endings, 123
reproductive organs, 119–122
female, 119–121
male, 121–122
respiratory system, 104–106
J-receptors, 105
rapidly adapting stretch receptors, 105
slowly adapting stretch receptors, 104–105
sensitization of, 123–127, 129
altered visceral sensations after repetitive stimulation or inflammation, 124
excitability changes, 124–125
effects of bradykinin and other algesic chemicals, 125
effects of hypoxia and ischemia, 125
effects of repetitive stimulation, 124
silent nociceptors, 125–127
urinary system, 115–119
bladder and urethra, 116–119
kidney and ureter, 115–116
Vitamin A, antioxidant properties, 144
Vitamin C
antioxidant properties, 143–144
synergistic actions with vitamin E, 148–149
Vitamin E
antioxidant properties, 142–143
synergistic actions with vitamin C, 148–149

W

Waist-to-hip ratio, 767
Weight loss
metabolic profile and, 797–798
regional adipose tissue response to, 797

X

X-ray analysis, electron microprobe, organelle calcium, 622–623

Z

Zinc
block of recombinant NMDA receptors, 748–749
NMDA receptors and, 751